[
  {
    "company": "monte_rosa",
    "program_name": "NEK7",
    "targets": [],
    "modalities": [],
    "e3_ligases": [
      "CRBN"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 9
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-8102",
    "targets": [
      "Caspase-1",
      "IL-1",
      "IL-17",
      "IL-1\u03b1",
      "IL-1\u03b2",
      "IL-6",
      "NEK7",
      "NLRP3",
      "TNF"
    ],
    "modalities": [
      "MGD",
      "Molecular Glue Degrader",
      "Neosubstrate-directed MGD",
      "molecular glue degrader"
    ],
    "e3_ligases": [
      "CRBN",
      "cereblon"
    ],
    "indications": [
      "ASCVD",
      "Allergic Diseases",
      "Asthma",
      "Atherosclerosis",
      "Cardio-Immuno-Metabolic",
      "Gout",
      "High CRP",
      "MASH",
      "Metabolic dysfunction-associated steatohepatitis",
      "Osteoarthritis",
      "Pericarditis",
      "Peripheral Inflammatory Diseases",
      "Pseudogout",
      "Recurrent pericarditis",
      "Rheumatology",
      "chronic inflammatory diseases",
      "gout",
      "high-risk CVD",
      "inflammation",
      "inflammatory disorders"
    ],
    "therapeutic_areas": [
      "CNS",
      "CVD",
      "Cardio-immunology",
      "Cardiometabolic Diseases",
      "Cardiovascular",
      "Cardiovascular Inflammation",
      "Inflammation",
      "blood",
      "cardiovascular",
      "cardiovascular disease",
      "immune",
      "inflammation"
    ],
    "clinical_phases": [
      "CRP PoC",
      "MAD",
      "Phase 1",
      "Phase 1 HV",
      "Phase 2",
      "Phase I",
      "Planned Phase 1 (PoC)",
      "SAD"
    ],
    "claims": [
      "31% reduction of fibrinogen",
      "55% reduction of endogenous IL-6 plasma levels",
      "85% decrease of hsCRP after 4 weeks of dosing",
      "85% sustained reduction of hsCRP",
      "94% of subjects show suppression of hsCRP to <2 mg/L",
      "94% subjects achieved reduction of hsCRP levels to <2 mg/L",
      "Achieved 80 \u2013 90% NEK7 Degradation in Peripheral Blood T Cells After Single and Multiple Dose Administration",
      "Active in human and non-human primates",
      "Catalytic MOA drives sustained PD effect",
      "Changes in CRP levels in subjects with high CRP",
      "Changes in gout/pseudogout flare pain or osteoarthritic pain",
      "Changes in levels of inflammatory cytokines",
      "Displays CNS-penetrance in cynomolgus monkey",
      "Excellent selectivity profile in different cell lines",
      "Exquisite selectivity enables high therapeutic index",
      "Favorable Drug-like Profile",
      "High degradation in immune and blood cells",
      "Highly selective NEK7 degradation",
      "In vivo NEK7 degradation leads to inhibition of NLRP3 inflammasome in ex vivo stimulation assay",
      "Inhibits IL-1 downstream of NLRP3 inflammasome activation",
      "Inhibits NLRP3 Activation",
      "Inhibits upstream pyroptosis & DAMP/cytokine release",
      "MRT-8102 exposure resulted in prolonged PD effect",
      "MRT-8102 has potential to avoid on-off pharmacodynamics and off-target toxicities of NLRP3 inhibitors",
      "MRT-8102 induced highly selective NEK7 degradation",
      "MRT-8102 induces degradation of NEK7 in vivo over several days",
      "MRT-8102 potently degraded NEK7",
      "No MGD induced tox findings in 2 GLP tox studies (VAV1, NEK7)",
      "Oral Bioavailability",
      "Potency, selectivity, and long-lasting pharmacodynamics differentiate from other IL-1/NLRP3 inflammasome approaches",
      "Potent",
      "Potent degradation of NEK7",
      "Potential to deplete both membrane receptors and intracellular signaling nodes",
      "Prevents IL-1 release",
      "Prolonged pharmacodynamic effect",
      "Rapid and sustained reduction of IL-1\u03b2 after ex-vivo stimulation",
      "Reduced ASC speck formation in human whole blood",
      "Reduced IL-1\u03b2 in human and cynomolgus monkey whole blood",
      "Reduces Caspase-1 activation",
      "Reduction in frequency of gout/pseudogout flares",
      "Safety, tolerability, and pharmacokinetics in healthy volunteers",
      "Selective",
      "Significant NEK7 degradation in various cyno brain regions 24h post treatment",
      "Significant reduction in median IL-6 levels to below CV risk threshold noted in subjects with elevated CRP",
      "Suppresses cytokine release in ex vivo-stimulated whole blood",
      "Up to 31% reduction in fibrinogen after 4 weeks of treatment",
      "durable NEK7 degrader",
      "favorable ADME/DMPK properties",
      "favorable AE profile",
      "induced rapid and compelling reduction in hsCRP",
      "induces catalytic NEK7 degradation",
      "induces selective NEK7 degradation",
      "inhibition of NLRP3 inflammasome",
      "inhibition of the NLRP3 inflammasome",
      "potent",
      "potent NEK7-directed MGD",
      "prevents pyroptotic cell death-mediated release of inflammatory cytokines and DAMPs",
      "selective",
      "therapeutic activity in rabbit gout model",
      "~80% inhibition in IL-1\u03b2 secretion noted in subjects with elevated CRP at baseline at doses ranging from 5 \u2013 200 mg",
      "~80-90% NEK7 degradation noted in T cells"
    ],
    "safety": [
      ">200-fold exposure margin over projected human efficacious dose in both species",
      "NOAEL was the highest dose tested, 150 mg/kg/day (rat) and 100 mg/kg/day (cyno)",
      "Negative Mini-Ames",
      "No MRT-8102 related clinical signs",
      "No SAEs",
      "No changes in immunophenotyping",
      "No concerns related to CV safety pharmacology (cyno)",
      "No concerns related to hERG",
      "No concerns related to in vitro off-targets",
      "No concerns related to in vivo respiratory or CNS safety pharmacology (rat)",
      "No concerns related to mutagenicity",
      "No concerns related to phototoxicity",
      "No degradation of other known CRBN neosubstrates",
      "No dose dependency",
      "No evidence of increased infection risk",
      "No gross or clinical pathology findings at any dose level",
      "No inhibition (EC50> 30 \u00b5M)",
      "No inhibition of hERG",
      "Oral bioavailability",
      "Safety and tolerability",
      "Safety and tolerability of 28 days dosing",
      "Safety, and tolerability of 28-day dosing",
      "Treatment-emergent AEs were mild to moderate",
      "Well tolerated with favorable safety profile with no SAEs",
      "no SAEs",
      "no adverse safety signals",
      "no severe AEs"
    ],
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 10
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 12
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 13
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 14
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 15
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 16
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 17
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 18
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 20
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 23
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 24
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 26
      },
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 28
      },
      {
        "document": "Keystone_FINAL.pdf",
        "slide": 11
      },
      {
        "document": "Monte Rosa AHA 2025 NEK7 Poster.pdf",
        "slide": 1
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 2
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 5
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 6
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 7
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 8
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 9
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 10
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 11
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 12
      },
      {
        "document": "EULAR 2025 NEK7 Presentation.pdf",
        "slide": 13
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 17
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 21
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 22
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 23
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 24
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 28
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 1
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 3
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 4
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 5
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 7
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 8
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 9
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 10
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 11
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 12
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 13
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 14
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 15
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 16
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 17
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 18
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 19
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 20
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 21
      },
      {
        "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
        "slide": 23
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-2359",
    "targets": [
      "AR",
      "CCND1",
      "CK1a",
      "CRBN",
      "Cyclin D1",
      "E2F",
      "GAPDH",
      "GSPT1",
      "GSPT2",
      "IKZF1",
      "IKZF3",
      "L-MYC",
      "MYC",
      "N-MYC",
      "SALL4",
      "ZFP91",
      "c-MYC"
    ],
    "modalities": [
      "MGD",
      "Molecular Glue Degrader",
      "molecular glue degrader",
      "molecular glue degraders"
    ],
    "e3_ligases": [
      "CRBN",
      "cereblon"
    ],
    "indications": [
      "AR positive prostate cancer",
      "ARV7-driven Prostate Cancer",
      "Breast cancer ER positive metastatic",
      "CRPC",
      "Cancers with MYC-induced Translational Addiction",
      "Castrate-Resistant Prostate Cancer",
      "Castration Resistant Prostate Cancer",
      "Castration-resistant Prostate Cancer",
      "DLBCL",
      "HG NE bladder carcinoma",
      "HR+/Her2- Breast Cancer (+Fulv)",
      "HR+/Her2- Breast cancer (+Fulv)",
      "Heme",
      "L-/N-MYC amplified tumors",
      "L-MYC High",
      "Lung Cancer",
      "Lung NE",
      "Lung cancer",
      "Lung cancer (NSCLC & SCLC)",
      "MYC High Lung Cancer",
      "MYC high Lung Cancer",
      "MYC-Driven NSCLC",
      "MYC-driven Cancer",
      "MYC-driven Cancer Cell Lines",
      "MYC-driven Malignancies",
      "MYC-driven NSCLC",
      "MYC-driven Tumors",
      "MYC-driven cancers",
      "MYC-driven lung cancer",
      "N-/L-MYC amplified solid tumors",
      "N-MYC High",
      "N-MYC High NSCLC",
      "N-MYC high NSCLC",
      "N-Myc high / NDRG1 low NSCLC",
      "NSCLC",
      "NSCLC N-MYC high SCLC/NE transformation",
      "NSCLC with SCLC/NE transformation",
      "Neuroendocrine Lung Cancer",
      "Neuroendocrine lung cancer",
      "Neuroendocrine tumors",
      "Prostate Cancer",
      "Prostate cancer (+Enza)",
      "Prostate cancer AR positive including AR-V7",
      "SCLC",
      "SCLC L/N-MYC high",
      "bladder carcinoma",
      "c-MYC High",
      "high-grade neuroendocrine tumors",
      "lung cancer",
      "lung cancers",
      "mCRPC",
      "mCRPC with AR mutations",
      "metastatic castration resistant prostate cancer",
      "metastatic castration resistant prostate cancer (CRPC)",
      "prostate cancer",
      "solid tumors with N-/L-MYC amplification",
      "therapy-resistant mCRPC"
    ],
    "therapeutic_areas": [
      "Lung Cancer",
      "Lymphoma",
      "NSCLC",
      "Neuroendocrine Lung Cancer",
      "Non-small Cell Lung Cancer",
      "Non-small Cell Lung Cancer (NSCLC)",
      "Oncology",
      "SCLC",
      "Small Cell Lung Cancer (SCLC)",
      "oncology",
      "prostate cancer"
    ],
    "clinical_phases": [
      "Ph I",
      "Phase 1",
      "Phase 1/2",
      "Phase 2",
      "Phase I",
      "Phase I/Ib",
      "first-in-man"
    ],
    "claims": [
      "1 PR (confirmed, -57%)",
      "1 PSA response (-90%)",
      "1 patient has SD",
      "1 patient with NSCLC and unclear biomarker status remains on therapy for > 7 months with stable disease",
      "100% PSA response",
      "100% disease control rate in the AR mutant population",
      "2 SDs",
      "2 have experienced a PR (1 confirmed, 1 unconfirmed)",
      "2 patients experienced a PR (1 confirmed, 1 unconfirmed)",
      "6/15 patients were identified as biomarker positive",
      "AR abundance (WT and V7) and proteins regulated by AR were significantly reduced",
      "AR pathway-relevant proteins",
      "Achieved Tumor Regressions in AR Mutant mCRPC",
      "Best-in-Class",
      "CRPC-relevant oncoproteins",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output in NCI-H1155",
      "Demonstrate dose dependent PK",
      "Demonstrate significant GSPT1 degradation at safe dose levels in PBMCs and tissue biopsies (60% based on preclinical data)",
      "Demonstrates Preferential Anti-tumor Activity",
      "Dose dependent exposure in line with preclinical PK",
      "Downregulates N-MYC",
      "Durable disease control noted in mutant and ARi na\u00efve patients",
      "Favorable ADME/DMPK profile",
      "Favorable ADMET profile",
      "Highly Optimized and Potent",
      "Highly Selective",
      "Highly Selective Recruiter and Degrader of GSPT1",
      "Highly selective against common neosubstrates of CRBN",
      "Induced selective GSPT1 degradation",
      "Induces GSPT1 degradation leading to N-MYC protein downregulation",
      "Induces Tumor Regressions in N-MYC-driven Xenograft Models",
      "Induces degradation of GSPT1",
      "Induces selective GSPT1 degradation",
      "Level of degradation equivalent across all dose levels, suggesting saturated PD response from 0.5 to 2 mg",
      "MRT-2359 + Pluvicto improved activity over single agents in enzalutamide-resistant, AR-V7 expressing 22Rv1 model",
      "MRT-2359 + enzalutamide drove tumor regressions in CDX models of CRPC with various AR alterations including LNCaP and VCaP",
      "MRT-2359 completely abrogates protein synthesis only in N-MYC high cell line",
      "MRT-2359 does not inhibit hERG",
      "MRT-2359 does not inhibit or induce major CYPs",
      "MRT-2359 doesn\u2019t inhibit hERG",
      "MRT-2359 has favorable ADMET profile",
      "MRT-2359 induces GSPT1 degradation leading to N-MYC protein downregulation in NCI-H1155",
      "MRT-2359 induces ribosome stalling at stop codon only in N-MYC high cell line",
      "MRT-2359 induces ribosome stalling only in N-MYC high cell line",
      "MRT-2359 is a selective GSPT1-directed MGD",
      "MRT-2359 is neither an inhibitor, nor an inducer of major CYPs",
      "MRT-2359 is orally bioavailable",
      "MRT-2359 preferentially impairs protein synthesis in tumor cells with high MYC expression",
      "MRT-2359 rapidly and completely abrogates protein synthesis only in N-MYC high cell line",
      "MRT-2359 reduced GSPT1 protein expression in human tissue biopsies",
      "MRT-2359 treatment significantly reduced AR-independent proteins",
      "MRT-2359 was more effective than enzalutamide at reducing AR activity",
      "MYC down modulation",
      "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359",
      "No clinical activity seen in biomarker negative patients",
      "No degradation of other known cereblon neosubstrates",
      "No food effect observed",
      "Oncogene addiction",
      "Oral bioavailable",
      "Oral dosing shows anti-tumor activity and regressions",
      "Orally Bioavailable",
      "Other CRPC-relevant oncogenes such as MYC and Cyclin D1 were also significantly reduced",
      "Overall disease control rate (DCR) of 64%",
      "PD modulation in PBMCs observed across all dose levels; level of degradation (~ 60%) in line with maximal degradation observed in preclinical studies using the same method",
      "Potent",
      "Potent and Highly Selective GSPT1-directed MGD",
      "Potent and Selective GSPT1 Degrader",
      "Potent inducer of GSPT1-cereblon proximity",
      "Preferential GSPT1 degradation",
      "Preferential anti-tumor activity in MYC-driven tumors",
      "Preferential antiproliferative activity in N-MYC high cell lines",
      "Preferential antiproliferative activity in high N-MYC cell lines",
      "Preferential inhibition of translation",
      "Resolution of liver metastases (-41% per RECIST 1.1)",
      "Selective",
      "Share potential preliminary efficacy signals in biomarker positive patients",
      "Shows favorable ADME/DMPK profile",
      "Synthetic lethality",
      "Transcriptional modulation of >200 MYC target genes",
      "Unconfirmed PR in NSCLC with SCLC/NE Transformation",
      "achieved compelling clinical activity in a subset of heavily pre-treated mCRPC patients with AR mutations",
      "affects MYC and its downstream targets",
      "clinical activity",
      "demonstrates robust anti-tumor activity preferentially in MYC-driven lung cancer models",
      "early signs of clinical activity",
      "favorable tolerability profile",
      "good oral bioavailability",
      "high selective effect (2.4 U)",
      "highly selective",
      "impairs protein synthesis",
      "optimal PD modulation",
      "optimal degradation kinetics",
      "optimal pharmacodynamic modulation",
      "oral bioavailability all species",
      "orally bioavailable",
      "overall disease control rate (DCR) of 64% in a total of 14 evaluable patients",
      "potent",
      "potent inducer of GSPT1-cereblon proximity",
      "preferential activity in MYC-driven cancer cells",
      "rationally designed",
      "rationally designed to be in the ADMET sweet-spot",
      "robust antitumor activity",
      "selective",
      "selective GSPT1-directed MGD"
    ],
    "safety": [
      "CEREP (Safety panel 44)",
      "CYP DDIs",
      "CYP DDIs (7 isoforms)",
      "CYP DDIs > 30 \u00b5M",
      "CYP2C19 @ 1.5 uM",
      "Caco2 (Efflux Ratio)",
      "Decreased appetite",
      "Diarrhea",
      "EC50 > 30 \u00b5M",
      "Fatigue",
      "Frequent dose interruptions due to bowel obstruction unrelated to MRT-2359",
      "Hypokalemia",
      "Leukopenia",
      "Nausea",
      "Neutropenia",
      "No activity observed in an in vitro panel of 44 safety targets",
      "No observed clinically significant hypocalcemia or hypotension/cytokine release syndrome",
      "Oral bioavailability all species",
      "Oral bioavailability all species ~50%",
      "Rash",
      "Safety assessments initiated",
      "Safety profile has been favorable",
      "Thrombocytopenia",
      "Vomiting",
      "Well-tolerated dose level",
      "hERG (patch clamp)",
      "hERG inhibition (patch clamp)",
      "hERG inhibition patch clamp",
      "hERG inhibition patch clamp EC50 > 30 \u00b5M",
      "mild or moderate manageable GI adverse events",
      "well tolerated",
      "well tolerated with mild or moderate manageable GI adverse events being the most frequent toxicities"
    ],
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 3
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 8
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 9
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 12
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 13
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 16
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 17
      },
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 21
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 1
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 7
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 8
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 9
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 10
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 11
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 12
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 13
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 14
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 15
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 16
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 17
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 18
      },
      {
        "document": "AACR2023__Owen_Final1.pdf",
        "slide": 19
      },
      {
        "document": "Keystone_FINAL.pdf",
        "slide": 15
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 1
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 3
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 5
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 6
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 7
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 8
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 9
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 10
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 12
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 13
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 15
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 17
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 21
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 23
      },
      {
        "document": "MRT-2359 Clincial Data Update.pdf",
        "slide": 24
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 1
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 4
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 5
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 6
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 8
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 9
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 10
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 11
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 12
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 13
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 15
      },
      {
        "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
        "slide": 16
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 31
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 33
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 34
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 36
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 39
      },
      {
        "document": "MRTx_AACR_2024_MRT2359_Prostate.pdf",
        "slide": 1
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 1
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 4
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 5
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 6
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 7
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 8
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 9
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 10
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 12
      },
      {
        "document": "34th EORTC-NCI-AACR Symposium.pdf",
        "slide": 13
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 2
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 5
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 6
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 7
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 8
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 9
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 10
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 11
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 12
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 13
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 14
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 15
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 16
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 17
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 18
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 19
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 20
      },
      {
        "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
        "slide": 23
      },
      {
        "document": "Monte Rosa AACR Poster April 2022.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 6
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 8
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 9
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 11
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 12
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 13
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 15
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 16
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 1
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 4
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 5
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 6
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 7
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 8
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 9
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 10
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 11
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 12
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 13
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 14
      },
      {
        "document": "AACR 2023_Gerald.pdf",
        "slide": 16
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modalities": [
      "MGD",
      "Molecular Glue Degrader",
      "molecular glue degrader",
      "molecular glue degraders"
    ],
    "e3_ligases": [
      "Cereblon",
      "cereblon"
    ],
    "indications": [
      "Collagen-Induced Arthritis",
      "IBD",
      "RA",
      "SLE",
      "Sj\u00f6gren\u2019s disease",
      "T Cell Transfer-Induced Colitis",
      "Ulcerative Colitis",
      "autoimmune diseases",
      "collagen-induced arthritis",
      "immune-mediated conditions",
      "immune-mediated diseases",
      "inflammatory bowel disease",
      "inflammatory diseases",
      "multiple sclerosis",
      "psoriasis",
      "rheumatoid arthritis",
      "systemic lupus erythematosus"
    ],
    "therapeutic_areas": [
      "Inflammation",
      "autoimmune diseases",
      "autoimmunity",
      "chronic inflammation",
      "immune-mediated diseases",
      "immunology",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "IND-enabling studies",
      "Phase 1",
      "Phase 2",
      "Phase I",
      "clinical trial",
      "completed testing in Healthy Subjects",
      "preclinical"
    ],
    "claims": [
      "Achieved Dose-Dependent VAV1 Degradation >90% in Peripheral Blood T Cells After Single and Multiple Dose Administration",
      "Attenuated IL-6 production by 60-90% across dose levels following B-cell stimulation",
      "Degradation by MRT-6160 exceeds 90%",
      "Favorable ADME/DMPK profile",
      "Induces selective VAV1 degradation",
      "Inhibits disease progression",
      "MRT-6160 Ameliorates T Cell Transfer-Induced Colitis Better than Standard of Care",
      "MRT-6160 attenuates B cell activation",
      "MRT-6160 attenuates T cell activation",
      "MRT-6160 has oral bioavailability",
      "MRT-6160 inhibited disease progression and colon weight:length ratio",
      "MRT-6160 inhibits EAE disease progression, severity, and incidence",
      "MRT-6160 inhibits T and B cell activation",
      "MRT-6160 inhibits T and B cell activation and effector functions",
      "MRT-6160 reduced expression of cytokines, tissue damage, and T cell pathway expression in the spinal cord",
      "MRT-6160 reduced expression of key disease-associated cytokines and tissue damage in the colon",
      "MRT-6160 reduces autoantibody production",
      "MRT-6160 reduces demyelination",
      "MRT-6160 reduces joint inflammation",
      "MRT-6160 reduces pro-inflammatory cytokine levels",
      "MRT-6160 reduces serum levels of pro-inflammatory cytokines",
      "MRT-6160 reduces spinal cord immune cell infiltration",
      "MRT-6160 reversed disease progression resulting in lower overall disease burden than standard of care",
      "Marked suppression of CD69 upregulation (>90%) in peripheral blood T and B cells following TCR stimulation",
      "Potent and Selective VAV1-directed MGD",
      "Reduces cytokine production in the mesenteric lymph node and colon",
      "Reduces inflammation-mediated damage of the colon",
      "Reduces kidney histopathology including lupus and interstitial nephritis",
      "Reduces secretion of key disease-associated serum cytokines",
      "Resulted in Sustained Suppression of TCR-mediated CD69 Activation following Single or Multiple Dose Administration",
      "Significant functional inhibition of T and B cells following a single dose administration",
      "Significantly (up to 99%) inhibited IL-2, IFN-\u03b3 and IL-17A secretion from whole blood derived T cells following ex vivo TCR stimulation",
      "Significantly attenuated CD69 upregulation on T and B cells following TCR stimulation, reflecting functional inhibition",
      "Similar results observed in peripheral blood B cells following BCR stimulation",
      "attenuates T and B cell effector functions",
      "attenuates antigen receptor-mediated activation and effector functions of T- and B-cells",
      "attenuates disease progression in the CIA autoimmune disease model",
      "deep VAV1 degradation of greater than 90%",
      "inhibiting disease progression in colitis",
      "inhibiting disease progression in collagen-induced arthritis",
      "inhibition of T cell proliferation",
      "inhibition of cytokine production in a dose-dependent manner",
      "inhibits TCR-induced activation",
      "inhibits disease progression",
      "prevents disease progression",
      "promising preclinical activity in mouse models of T and T/B cell-mediated disease",
      "rapidly degrades Vav1 in vivo",
      "reduces colon inflammation",
      "reduces kidney glomerular and interstitial nephritis",
      "reduces pro-inflammatory cytokine production",
      "significant T and B cell functional inhibition",
      "significant inhibition of cytokines commonly associated with multiple immune-mediated diseases",
      "successful and specific degradation of VAV1 in vitro and in vivo"
    ],
    "safety": [
      "> 50%",
      "> 50% oral bioavailability all species",
      "EC50 > 30 \u00b5M",
      "IC50 > 30 \u00b5M",
      "MRT-6160 was well tolerated with no serious adverse events (SAE)",
      "No degradation of other known cereblon neosubstrates",
      "Observed treatment-emergent adverse events (TEAE) were mild (82%) or moderate (18%) and self-limiting",
      "Overall TEAE frequency was similar between MRT-6160 and placebo",
      "Safety and tolerability",
      "Safety, PK and PD Data from SAD and MAD Healthy Volunteers",
      "TEAE observed in 2 or more subjects treated with MRT-6160: SAD: pain from vessel puncture (2), MAD: cough (2), diarrhea (3), feeling hot (4), headache (5), nasal congestion (2), oropharyngeal pain (3) and pyrexia (2)",
      "early insights into safety",
      "inherent risk of malignancy",
      "risk of serious and opportunistic infections"
    ],
    "evidence": [
      {
        "document": "Keystone2024_FINAL.pdf",
        "slide": 17
      },
      {
        "document": "FOCIS_2025_MRT6160_EAE.pdf",
        "slide": 1
      },
      {
        "document": "MRT_EULAR_2024_MRT6160_CIA_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "MRT_ECTRIMS_2025_MRT6160_EAE_FINAL_PDF.pdf",
        "slide": 1
      },
      {
        "document": "MRT_DDW_2024_MRT6160_IBD_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 3
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 4
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 6
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 7
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 8
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 9
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 11
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 12
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 13
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 14
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 15
      },
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 30
      },
      {
        "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
        "slide": 14
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 1
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 2
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 3
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 6
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 7
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 8
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 9
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 10
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 11
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 12
      },
      {
        "document": "Keystone Symposia - MRT-6160.pdf",
        "slide": 13
      },
      {
        "document": "MRT_ACR_2023_MRT6160_CIA_FINAL_PDF.pdf",
        "slide": 1
      },
      {
        "document": "MRT_ACR_2025_MRT6160_SjD_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 17
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 20
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 21
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 22
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 23
      },
      {
        "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
        "slide": 24
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "GSPT1",
    "targets": [
      "Myc"
    ],
    "modalities": [
      "molecular glue degraders"
    ],
    "e3_ligases": [],
    "indications": [
      "Myc-driven cancers"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
        "slide": 6
      },
      {
        "document": "European Protein Degradation Congress - September 21, 2021.pdf",
        "slide": 2
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-8046",
    "targets": [
      "NEK7"
    ],
    "modalities": [
      "MGD"
    ],
    "e3_ligases": [],
    "indications": [
      "gout"
    ],
    "therapeutic_areas": [
      "inflammation"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
        "slide": 21
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-6797",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
        "slide": 17
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "NEK7-MGD",
    "targets": [
      "NEK7"
    ],
    "modalities": [],
    "e3_ligases": [
      "CRBN"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "Keystone_FINAL.pdf",
        "slide": 13
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-9643",
    "targets": [
      "CDK2"
    ],
    "modalities": [
      "MGD",
      "Molecular Glue Degrader"
    ],
    "e3_ligases": [
      "CRBN"
    ],
    "indications": [
      "ER+ Breast Cancer",
      "HR-Positive/HER2-Negative Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "CDK2 degradation achieves equivalent efficacy compared to anti-CDK4/6 and anti-estrogen standard of care",
      "CDK2 degradation delays resistance to CDK4/6 inhibition",
      "CDK2 degradation inhibits CDK2-dependent cancer cell proliferation",
      "Favorable ADME/DMPK profile",
      "Induces Strong Pathway Suppression",
      "Induces highly selective CDK2 degradation",
      "Induces robust pathway suppression in combination with breast cancer SoC",
      "MRT-9643 counteracts resistance to CDK4/6 inhibition in HR-positive cells",
      "MRT-9643 demonstrates activity and pathway suppression in combination with CDK4/6 inhibition",
      "MRT-9643 exhibits potency, selectivity, and favorable drug-like properties",
      "MRT-9643 inhibits proliferation of CDK2-dependent cancer cells",
      "No degradation of other known CRBN neosubstrates",
      "Potent and Highly Selective CDK2-directed MGD",
      "Readily degrades CDK2 in vivo",
      "induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant",
      "induces strong TGI in combination with CDK4/6 inhibitor in vivo",
      "induces strong TGI in combination with CDK4/6 inhibitors in vivo"
    ],
    "safety": [
      "IC50 15 - >50 \u00b5M",
      "hERG inhibition patch clamp"
    ],
    "evidence": [
      {
        "document": "P5-01-26_Ilic-Widlund.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 7
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 8
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 9
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 10
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 11
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 12
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 13
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "AR H875Y Mutation",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "Refractory CRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PR"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 40
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-50969",
    "targets": [
      "Cyclin E1",
      "E2F targets",
      "cyclin E1"
    ],
    "modalities": [
      "Molecular Glue Degrader"
    ],
    "e3_ligases": [
      "CRBN"
    ],
    "indications": [
      "Breast cancer",
      "CCNE1 amplified breast cancer",
      "CCNE1 amplified gastric cancer",
      "Endometrial cancer",
      "Gastric cancer",
      "Ovarian cancer",
      "breast cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "First-in-class cyclin E1 degrader for cyclin E1 amplified cancers",
      "Induction of senescence by cyclin E1 degradation is RB-dependent",
      "Loss of RB blunts growth suppression induced by MRT-50969",
      "MRT-50969 degrades cyclin E1 and inhibits downstream pathway activity in vivo",
      "MRT-50969 induces robust G1/S cell cycle arrest",
      "MRT-50969 inhibits tumor growth in CCNE1 amplified gastric cancer model",
      "MRT-50969 is a potent and highly selective cyclin E1-directed MGD",
      "MRT-50969 is orally bioavailable and shows anti-tumor activity in a dose dependent manner in CCNE1-amplified cell line-derived xenograft models",
      "MRT-50969 shows superior differential activity in CCNE1 dependent cell lines compared to clinical-stage CDK2 inhibitors",
      "degrades cyclin E1",
      "inhibits tumor growth"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 44
      },
      {
        "document": "ENA_2024_CCNE1_poster.pdf",
        "slide": 1
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 18
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 19
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 20
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 22
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 24
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 25
      },
      {
        "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
        "slide": 26
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-51443",
    "targets": [
      "CDK2"
    ],
    "modalities": [
      "Molecular Glue Degrader"
    ],
    "e3_ligases": [
      "CRBN"
    ],
    "indications": [
      "ER+ Breast Cancer",
      "HR-Positive/HER2-Negative Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "MRT-51443 counteracts resistance to CDK4/6 inhibition in HR+ breast cancer models.",
      "MRT-51443 displays superior selectivity compared to clinical CDK2 inhibitors.",
      "MRT-51443 exhibits favorable PK and PD profiles.",
      "MRT-51443 induces robust tumor regression in combination with CDK4/6 inhibition and Fulvestrant.",
      "MRT-51443 inhibits proliferation of CDK2-dependent cancer cells.",
      "MRT-51443 is a potent and highly selective CDK2-directed molecular glue degrader.",
      "induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant",
      "substantially reduces tumor growth vs. ribo + fulv"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
        "slide": 45
      },
      {
        "document": "Selective Targeting of CDK2 Using Molecular Glue Degraders.pdf",
        "slide": 1
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "LBA004",
    "targets": [
      "GSPT1"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "Myc-driven cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
        "slide": 1
      }
    ]
  },
  {
    "company": "monte_rosa",
    "program_name": "MRT-048",
    "targets": [
      "GSPT1",
      "Myc",
      "p4EBP1"
    ],
    "modalities": [],
    "e3_ligases": [
      "cereblon"
    ],
    "indications": [
      "Breast Cancer",
      "Myc-driven Cancers"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Myc gene signatures are strongly down-regulated following treatment with MRT-048",
      "Potent anti-tumor activity",
      "Target engagement demonstrated"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
        "slide": 5
      },
      {
        "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
        "slide": 6
      },
      {
        "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
        "slide": 7
      },
      {
        "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
        "slide": 8
      },
      {
        "document": "European Protein Degradation Congress - September 21, 2021.pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-474",
    "targets": [
      "CRP",
      "IL-1\u03b2",
      "IL-6",
      "IRAK1",
      "IRAK2",
      "IRAK3",
      "IRAK4",
      "MyD88",
      "SAA",
      "TLRs",
      "TRAF6"
    ],
    "modalities": [
      "Oral Degrader",
      "Oral QD Small Molecule Degraders",
      "oral",
      "oral degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "AD",
      "Asthma",
      "Atopic Dermatitis",
      "CAPS",
      "COPD",
      "CRSwNP",
      "Generalized Pustular Psoriasis",
      "Gout",
      "HS",
      "Healthy Volunteers",
      "Hidradenitis Suppurativa",
      "IBD",
      "Lupus",
      "Macrophage Activation Syndrome",
      "Multiple Sclerosis",
      "Psoriasis",
      "RA",
      "Rheumatoid Arthritis",
      "atopic dermatitis",
      "hidradenitis suppurativa",
      "immune-inflammatory",
      "inflammatory diseases",
      "other1"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "Immunology",
      "Inflammation",
      "Oncology",
      "Th1-Th17",
      "Th2",
      "anti-inflammatory",
      "dermatology",
      "immune-inflammatory",
      "immune-inflammatory diseases",
      "inflammation",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph2",
      "Phase 1",
      "Phase 2",
      "clinical stage"
    ],
    "claims": [
      "Achieved >98% IRAK4 Degradation",
      "Achieved Near Complete and Sustained IRAK4 Degradation with Multiple Daily Oral Doses (14 Days)",
      "Associated with functional inhibition of TLR- and IL-1b-stimulated cytokine production",
      "Associated with up to 85% inhibition of multiple disease-relevant cytokines and chemokines in ex vivo TLR stimulation assay at 100 mg dose",
      "Best-in-pathway profile opportunity",
      "Compelling Data and Early POC",
      "Competitive efficacy vs. pathway biologics",
      "Comprehensive understanding of degradation kinetics across cell types to enable human translation",
      "Convenience of once-daily oral dosing",
      "Dose-dependent IRAK4 degradation in skin",
      "Dose-dependent IRAK4 degradation in skin of >50%",
      "Early signs of strong clinical activity",
      "Favorable safety profile",
      "Generally well tolerated at doses up to 200 mg with no SAEs",
      "IRAK4 blocks inflammation in blood and skin of HS and AD patients",
      "IRAK4 degradation of 80-90% in PBMC using Flow Cytometry",
      "IRAK4 degradation reduces signs and symptoms of HS and AD, while IRAK4 SMI inactive in Phase 2 HS trial",
      "IRAK4 knockdown of \u226585% in whole blood achieved anti-inflammatory effect comparable to potent corticosteroids or approved standard of care drugs",
      "KT-474 DC50 = 2.1 nM in human immune cells",
      "KT-474 better able to inhibit IL-6 under both LPS and LPS + IL-1\u03b2 than clinically active IRAK4 SM kinase inhibitor PF-06550833",
      "KT-474 only degraded IRAK4 in human immune cells at concentration 10-fold above the DC90",
      "MAD 2 through 4 approached Lower Limit of Quantitation (LLOQ)",
      "Mean IRAK4 levels at 200 mg dose nearing LLOQ by Day 14, with knockdown up to 90% at 200 mg",
      "Non-adverse, self-limiting QTcF prolongation in 10-20 msec range was neither dose- nor exposure-dependent",
      "Only Degrader Can Fully Block Inflammation",
      "Plateau in IRAK4 Reduction after 14 days in PBMC after 100 mg",
      "Potent degradation in PBMC subsets and skin cells including fibroblasts, with single-digit nM DC50",
      "Potential for broad anti-inflammatory effect",
      "Promising clinical activity",
      "Recovery towards baseline by Day 28 (2 weeks after last dose)",
      "Reduced IRAK4 to Near LLOQ in the Skin",
      "Reduction to near lower limit of quantification with Mass Spectrometry",
      "Robust IRAK4 degradation",
      "Selective and Potent IRAK4 Degrader Active in Multiple Cell Types",
      "Selectivity in PBMC",
      "Steady state IRAK4 reduction achieved between Days 7 and 14",
      "Superiority in Phase 1/2",
      "Systemic suppression of proinflammatory cytokines and chemokines",
      "best-in-class",
      "demonstrating degrader vs. small molecule inhibitors (SMI) biological differentiation",
      "excellent preclinical to clinical translation and predictability of IRAK4 degradation",
      "marked reduction of IRAK4 protein in blood and skin",
      "modest, non-adverse QTcF prolongation observed",
      "potential best in class oral drug",
      "potential best in class profile in I/I",
      "prolonged suppression of IRAK4 in blood and skin",
      "promising clinical activity exceeding benchmark placebo rates",
      "proof of biology (broad inhibition of cytokine induction)",
      "proof of mechanism (IRAK4 degradation)",
      "robust degradation of IRAK4 associated with systemic anti-inflammatory effect",
      "safety, PK and PD comparable to healthy volunteers",
      "strong and broad inhibition of whole blood ex vivo cytokine induction",
      "superior clinical potential over SMI"
    ],
    "safety": [
      "Favorable safety profile",
      "Generally well tolerated at doses up to 200 mg with no SAEs",
      "Generally well-tolerated across all dose groups",
      "Non-adverse, self-limiting QTcF prolongation in 10-20 msec range",
      "Safety & tolerability",
      "Safety, PK and PD comparable to healthy volunteers",
      "demonstrated fidelity of translation of PK, PD and safety across three clinical programs in I/I and oncology patients",
      "modest, non-adverse QTcF prolongation observed to spontaneously resolve",
      "safety, PK and PD comparable to healthy volunteers",
      "shown to be safe and well-tolerated"
    ],
    "evidence": [
      {
        "document": "Kymera R.pdf",
        "slide": 14
      },
      {
        "document": "Kymera R.pdf",
        "slide": 16
      },
      {
        "document": "Kymera R.pdf",
        "slide": 25
      },
      {
        "document": "Kymera R.pdf",
        "slide": 27
      },
      {
        "document": "Kymera R.pdf",
        "slide": 29
      },
      {
        "document": "Kymera R.pdf",
        "slide": 30
      },
      {
        "document": "Kymera R.pdf",
        "slide": 31
      },
      {
        "document": "Kymera R.pdf",
        "slide": 32
      },
      {
        "document": "Kymera R.pdf",
        "slide": 34
      },
      {
        "document": "Kymera R.pdf",
        "slide": 38
      },
      {
        "document": "Kymera R.pdf",
        "slide": 71
      },
      {
        "document": "Kymera R.pdf",
        "slide": 72
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 21
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 24
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 25
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 26
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 28
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 29
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 31
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 34
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 35
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 36
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 37
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 38
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 42
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 95
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 99
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 4
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 23
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 26
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 27
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 32
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 33
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 35
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 36
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 39
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 41
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 50
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 59
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 61
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 62
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-621",
    "targets": [
      "CCL13/MCP-4",
      "CCL17/TARC",
      "CCL18/PARC",
      "CCL26/Eotaxin-3",
      "CXCL1/GRO-\u237a",
      "IL-13",
      "IL-31",
      "IL-4",
      "KRT16/Keratin 16",
      "MMP12",
      "OSMR/Oncostatin-M receptor",
      "PI3/Peptidase inhibitor 3",
      "POSTN/Periostin",
      "S100A12",
      "STAT6",
      "TSLP"
    ],
    "modalities": [
      "Oral Degrader",
      "Oral Small Molecule Degrader",
      "degrader",
      "oral",
      "oral small molecule"
    ],
    "e3_ligases": [],
    "indications": [
      "AD",
      "Allergic Rhinitis",
      "Allergic Th2 Inflammation",
      "Alzheimer's Disease",
      "Asthma",
      "Atopic Dermatitis",
      "BP",
      "Bullous Pemphigoid",
      "COPD",
      "CPG",
      "CRSwNP",
      "CSU",
      "CU",
      "Chronic Obstructive Pulmonary Disease",
      "Chronic Rhinosinusitis with Nasal Polyps",
      "Chronic Spontaneous Urticaria",
      "Dupilumab-like Activity",
      "EoE",
      "Eosinophilic Esophagitis",
      "Moderate to Severe Eosinophilic Asthma",
      "Moderate/Severe Atopic Dermatitis",
      "PN",
      "Prurigo Nodularis",
      "Severe AD",
      "TH2 diseases",
      "Type 2 Allergic Diseases",
      "Type 2 Diseases",
      "Type 2 inflammation",
      "allergic rhinitis",
      "asthma",
      "atopic dermatitis",
      "others"
    ],
    "therapeutic_areas": [
      "Allergic Th2 Inflammation",
      "Allergic Type 2 Inflammation",
      "Dermatological",
      "Dermatology",
      "GI",
      "Gastrointestinal",
      "Immunology",
      "Respiratory",
      "Th2 diseases",
      "Type 2 Diseases",
      "Type 2 Inflammatory Diseases",
      "Type 2 diseases",
      "Type 2 market",
      "atopic dermatitis",
      "dermatology",
      "gastroenterology",
      "immunology",
      "inflammatory diseases",
      "lung inflammation",
      "respiratory"
    ],
    "clinical_phases": [
      "FIH: 2H 2024",
      "Ph1",
      "Ph1b",
      "Ph2b",
      "Ph3",
      "Phase 1",
      "Phase 1/2",
      "Phase 1a",
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      "100% responder rate in ACQ-5",
      "56% median FeNO reduction at Day 29",
      "74% median TARC reduction similar to dupilumab at week 4 when stratifying for patients with similar baseline TARC levels",
      "90% STAT6 degradation leads to comparable or superior in vivo efficacy to dupilumab in asthma models",
      ">90% STAT6 Degradation in Blood Across All Dose Levels",
      ">90% STAT6 degradation in blood in all doses above 1.5 mg",
      ">95% Mean STAT6 Degradation Achieved at Doses of 75 mg or Greater",
      "Achieved 76% Overall Mean Reduction in SCORAD-Sleeplessness",
      "Achieved >90% STAT6 Degradation in Blood at All Dose Levels Above 1.5 mg",
      "Achieved Complete STAT6 Degradation in Skin",
      "Achieved Deep STAT6 Degradation in Blood and Skin",
      "Achieved Median Serum Eotaxin-3 Reduction of up to 73%",
      "Achieved Median Serum IgE Reduction of up to 14%",
      "Achieved Median TARC Reduction of 74% in Patients with TARC Levels Comparable to Dupilumab AD Studies",
      "Achieved Rapid and Robust Reductions in EASI and SCORAD Across All Patients",
      "Achieved Robust Clinical Improvement Across EASI-50, EASI-75, and vIGA-AD 0/1 Measures",
      "Achieved Robust and Consistent Reductions in Itch Across Independent Clinical Measures",
      "Achieved mean changes of -0.8 in RQLQ",
      "Achieved mean changes of -0.8 points in RQLQ",
      "Achieved mean changes of \u20130.9 in TNSS",
      "Achieved mean changes of \u20130.9 points in TNSS",
      "Achieved robust clinical improvement across EASI-50 (76% overall), EASI-75 (29% overall) and vIGA-AD (19% overall)",
      "Achieved up to 33% Reduction in FeNO in AD Patients",
      "Achieves Dose Dependent Deep Degradation of STAT6 in vivo with Low Oral Doses",
      "Best-in-pathway profile opportunity",
      "Blocked IL-4 and IL-13 signaling in human cells and in vivo systems equally or more potently than dupilumab",
      "Blocks Th2 Inflammation in Vivo",
      "Blocks Type 2 inflammation in lungs (FeNO) and relieves asthma symptoms (ACQ-5)",
      "Blocks Type 2 inflammation in skin and impacts AD lesions (EASI, vIGA-AD, and skin transcriptomic changes)",
      "Clinical activity",
      "Comparable in vivo efficacy to IL-4R\u03b1 saturating dose of Dupilumab",
      "Compelling Clinical Profile",
      "Compelling Preclinical Profile",
      "Complete Degradation Achieved at Doses of 50 mg or Greater",
      "Complete STAT6 Degradation in Blood",
      "Complete STAT6 degradation achieved at doses \u22655 mg",
      "Complete STAT6 degradation achieved in both blood and skin in all doses \u22655 mg",
      "Complete STAT6 degradation selectivity in human PBMC at 100xDC90",
      "Complete STAT6 degradation selectivity in human PBMC proteome at 100 x DC90",
      "Deep STAT6 Degradation in Blood and Skin",
      "Deep STAT6 degradation",
      "Deep STAT6 degradation >94/95% in HV & patients with AD in skin",
      "Deep STAT6 degradation >95% in HV & patients with AD in blood",
      "Deep STAT6 degradation in blood and skin",
      "Deep degradation maintained throughout dosing period",
      "Deep degradation of STAT6 in NHP after 14 days of daily oral dosing",
      "Deep skin degradation of 94% in both dose groups with multiple patients\u2019 STAT6 levels below the LLOQ",
      "Deep skin degradation with multiple patients\u2019 STAT6 levels below the LLOQ",
      "Degradation Maintained for 28 Days Across Both Dose Cohorts",
      "Degrades STAT6 at Low Oral Doses in All Relevant Tissues",
      "Demonstrate that KT-621 has a dupilumab-like biomarker signature in blood and skin lesions",
      "Dose Responsive STAT6 Degradation in Dog Blood",
      "Dupi-like profile",
      "Dupilumab-like Activity in a Pill",
      "Dupilumab-like activity",
      "Dupilumab-like activity with oral small molecule profile",
      "Dupilumab-like efficacy",
      "Dupilumab-like impact on EASI, SCORAD and multiple measures of pruritus",
      "Dupilumab-like reductions in TARC, Eotaxin-3 and IgE",
      "Dupilumab-like reductions in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions",
      "Early evidence of activity in asthma and allergic rhinitis",
      "Efficacy and safety in two initial Th2 diseases",
      "Excellent Preclinical Activity Comparable or Superior to Dupilumab",
      "Exquisite Selectivity",
      "Favorable safety profile",
      "First known demonstration of FeNO reduction in AD patients",
      "Full IL-4 and IL-13 functional inhibition with picomolar IC50s superior to dupilumab",
      "Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab",
      "Full inhibition of IL-4/IL-13 pathways more potent than dupilumab",
      "Fully Blocks IL-4/13 Pathway",
      "IC50\u2019s Lower than Dupilumab",
      "IL-4/IL-13 Pathway Inhibition",
      "IgE reduction comparable to dupilumab data in AD studies at week 41",
      "KT-621 reached dupilumab-like TARC inhibition",
      "KT-621 was well-tolerated with a safety profile undifferentiated from placebo",
      "Maximal degradation seen as quickly as 4 hours after single dose",
      "Mean % Change from Baseline at D29 Overall: -40%",
      "Mean % Change from Baseline at D29 for KT-621 100 mg QD: -47%",
      "Mean % Change from Baseline at D29 for KT-621 200 mg QD: -35%",
      "Meaningful improvements of clinical endpoints and patient-reported outcomes",
      "Meaningful improvements on clinical endpoints and PROs",
      "Median STAT6 degradation of 94% in skin in both dose groups after 4 weeks of treatment using targeted Mass Spec",
      "Median STAT6 degradation of 98% in blood in both dose groups after 4 weeks of treatment",
      "Median STAT6 degradation of 98% in blood in both dose groups maintained throughout the treatment period",
      "Most subjects with STAT6 levels below LLOQ at doses of \u22655 mg",
      "Multiple subjects with STAT6 levels below LLOQ at doses of 75 mg or greater",
      "No other STATs are degraded to any extent",
      "No rescue therapy required during treatment period",
      "Only STAT6 Degradation Has the Potential to Lead to Dupilumab-Like Pathway Inhibition",
      "Only STAT6 degradation has the potential to fully block IL-4/IL-13 signaling with an oral daily drug",
      "Ph3 dose selection for clinical activity franchise",
      "Plasma PK profile at 100 and 200 mg similar to healthy volunteer study",
      "Potential for Dupilumab-like Activity",
      "Potential for Dupilumab-like Activity in a Pill",
      "RQLQ responder rate was 33%",
      "Rapid and robust mean Peak Pruritus NRS and SCORAD-Itch reduction in both dose cohorts",
      "Rapid and robust mean SCORAD-Sleeplessness reduction in both dose cohorts",
      "Rapid and robust reduction of TARC across both dose cohorts",
      "Reduction exceeds the dupilumab 52-week results of 51% median reduction in CRSwNP trial and 38% in asthma trial",
      "Reduction of IL-31",
      "Reductions in Multiple Disease-Relevant Type 2 Biomarkers",
      "Reductions seen as early as Day 8 without apparent plateau during treatment duration",
      "Relieves allergic rhinitis symptoms (TNSS, RQLQ)",
      "Results in line or superior to published data for dupilumab, with strong TARC and Eotaxin-3 reductions",
      "Robust Degradation in Relevant Cell Types",
      "Robust STAT6 Degradation",
      "Robust STAT6 Degradation in Blood and Skin Following Low Daily Oral Doses",
      "Robust STAT6 degradation observed at first time point measured (8hr) for all doses above 1.5 mg",
      "Robust activity in asthma and AD in mouse models",
      "Robust and consistent reductions in itch (PPNRS, SCORAD Itch, IL-31)",
      "Robust degradation maintained as long as 4 days after single dose with recovery by Day 14",
      "Robust efficacy shown in in vivo models equal or superior to dupilumab",
      "Robust inhibition of several biomarkers, comparable/superior to published dupilumab data",
      "Robust reduction of pruritogenic cytokine IL-31",
      "Robust reductions in Type 2 biomarkers",
      "Robust reductions in Type 2 biomarkers in blood, skin lesions and lung (FeNO)",
      "STAT6 Degradation in All Relevant Tissues in NHP",
      "STAT6 is degraded in key disease-relevant tissues: blood, spleen, skin and lung",
      "Safety & tolerability",
      "Safety and tolerability",
      "Similar effect in patients with low or high baseline EASI/TARC",
      "Single doses of KT-621 achieved rapid, deep and prolonged STAT6 degradation in blood",
      "Steady-state maximum degradation achieved as early as 8hr post-first dose with recovery starting at 4 days post-last dose",
      "Strong fidelity of translation from Phase 1a healthy volunteer study to AD patients",
      "Strong translation from healthy volunteer study",
      "TNSS responder rate was 57%",
      "Well-tolerated in preclinical studies",
      "blocked IL-4/13 biomarkers equally or numerically better than dupilumab",
      "can degrade STAT6 to depletion with low oral doses",
      "demonstrated meaningful improvements on Type 2 biomarkers in blood and skin",
      "disrupt a biologics-dominated market",
      "has the potential to offer 'what patients want'",
      "improvements on FeNO in AD and comorbid asthma patients",
      "improvements on clinical endpoints in patients with AD, comorbid asthma and allergic rhinitis",
      "oral, biologics-like profile",
      "potential to broaden clinical access",
      "potently degrades STAT6 across multiple preclinical species",
      "results in line with or in some cases numerically exceeded published data for dupilumab at week 4",
      "robustly degrade STAT6 in blood and skin at doses that are safe and well-tolerated",
      "safely and deeply degraded STAT6",
      "transforming the treatment of AD, asthma, and other Type 2 diseases",
      "\u226595% mean STAT6 degradation at doses \u22655 mg"
    ],
    "safety": [
      "4 months rat and NHP GLP tox",
      "Dosing for 28 days",
      "Embryofetal development tox in rat, rabbit and NHP",
      "Favorable safety profile",
      "Favorable safety profile: well-tolerated across all dose levels with safety profile undifferentiated from placebo",
      "Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose with up to 4 months of dosing",
      "No AEs at any doses in: 4 weeks rat and NHP GLP tox",
      "No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthralgias",
      "No SAEs",
      "No SAEs or Severe AEs",
      "No Serious Adverse Events",
      "No Severe AEs",
      "No Severe Adverse Events",
      "No TRAEs >1 subject",
      "No Treatment Related AE (TRAE) reported in >1 participant",
      "No adverse safety findings in any doses of 4-week GLP tox studies in NHP and rodents",
      "No clinically relevant changes in vital signs, laboratory tests or ECGs",
      "No clinically relevant changes in vital signs, laboratory tests, and ECGs",
      "No dose dependent pattern in Treatment Emergent Adverse Events (TEAEs)",
      "No dose dependent pattern in the TEAEs",
      "No dose-dependent pattern in the TEAEs",
      "No related TEAEs leading to discontinuation",
      "No related TEAEs or TEAEs leading to discontinuation",
      "No treatment related AE reported in >1 participant",
      "Safety & tolerability of escalating single and multiple doses of KT-621",
      "Safety profile similar to Phase 1a healthy volunteer trial",
      "Safety profile undifferentiated from placebo",
      "Safety, PK, STAT6 degradation, Th2 biomarkers in blood and skin lesions, clinical activity (EASI, pruritus, IGA)",
      "Well Tolerated Across All Doses Evaluated Undifferentiated from Placebo",
      "Well Tolerated Across All Doses Evaluated and Safety Profile Undifferentiated from Placebo",
      "Well tolerated",
      "Well tolerated at 90%+ degradation",
      "Well tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose",
      "Well-tolerated",
      "Well-tolerated across all dose levels",
      "Well-tolerated and favorable safety profile",
      "Well-tolerated and favorable safety profile similar to Phase 1a healthy volunteer study",
      "Well-tolerated in multiple preclinical safety studies at >40x efficacious concentration",
      "Well-tolerated with favorable safety at both 100 mg and 200 mg",
      "no side effects or safety issues",
      "safely",
      "safely and deeply degraded STAT6"
    ],
    "evidence": [
      {
        "document": "Kymera R.pdf",
        "slide": 18
      },
      {
        "document": "Kymera R.pdf",
        "slide": 39
      },
      {
        "document": "Kymera R.pdf",
        "slide": 43
      },
      {
        "document": "Kymera R.pdf",
        "slide": 44
      },
      {
        "document": "Kymera R.pdf",
        "slide": 45
      },
      {
        "document": "Kymera R.pdf",
        "slide": 46
      },
      {
        "document": "Kymera R.pdf",
        "slide": 47
      },
      {
        "document": "Kymera R.pdf",
        "slide": 48
      },
      {
        "document": "Kymera R.pdf",
        "slide": 49
      },
      {
        "document": "Kymera R.pdf",
        "slide": 50
      },
      {
        "document": "Kymera R.pdf",
        "slide": 51
      },
      {
        "document": "Kymera R.pdf",
        "slide": 52
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 16
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 17
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 18
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 20
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 21
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 22
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 23
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 24
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 25
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 13
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 14
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 16
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 17
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 18
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 19
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 20
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 22
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 23
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 25
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 27
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 28
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 29
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 30
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 31
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 32
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 33
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 34
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 35
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 53
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 56
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 57
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 58
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 60
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 1
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 3
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 9
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 11
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 12
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 13
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 14
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 15
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 22
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 23
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 27
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 28
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 29
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 30
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 31
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 32
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 33
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 35
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 36
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 38
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 39
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 40
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 41
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 42
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 43
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 44
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 45
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 46
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 47
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 48
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 49
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 50
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 53
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 55
      },
      {
        "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
        "slide": 56
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 1
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 2
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 12
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 13
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 15
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 16
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 17
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 18
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 19
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 21
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 22
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 23
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 24
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 25
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 26
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 27
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 28
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 29
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 33
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 34
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 35
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 36
      },
      {
        "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
        "slide": 37
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modalities": [
      "Oral",
      "oral degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "IBD",
      "Inflammatory Bowel Disease",
      "Lupus",
      "PsA",
      "PsO",
      "Type I IFN & IL-23 inflammation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "FIH",
      "Phase 1"
    ],
    "claims": [
      "Achieved Dose Dependent Deep Degradation of TYK2 in vivo with Low Oral Doses",
      "Best-in-pathway profile opportunity",
      "Full TYK2 degradation demonstrated by KT-294 leads to superior pathway inhibition to existing SMIs and potentially reach biologic-like activity",
      "Fully Inhibits Type I IFN and IL-12/23 and Spares IL-10/22",
      "Highly Selective Picomolar TYK2 Degrader",
      "In NHP, KT-294 can degrade TYK2 to depletion with low oral doses",
      "KT-294 does not inhibit IL-10, which is important in IBD",
      "KT-294 fully inhibits Type I IFN",
      "KT-294 potently degrades TYK2 across multiple preclinical species",
      "Mega-blockbuster potential for oral degrader with biologic-like activity that is superior to TYK2 SMI",
      "Only TYK2 degradation recapitulates the human LOF phenotype of full pathway inhibition of Type I IFN, IL-12 and IL-23 and sparing of IL-10",
      "Potential Best-in-Class Opportunity with Biologic-like Profile",
      "recapitulates LOF phenotype: biologic-like activity and convenience of oral pill"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "Kymera R.pdf",
        "slide": 20
      },
      {
        "document": "Kymera R.pdf",
        "slide": 53
      },
      {
        "document": "Kymera R.pdf",
        "slide": 57
      },
      {
        "document": "Kymera R.pdf",
        "slide": 59
      },
      {
        "document": "Kymera R.pdf",
        "slide": 60
      },
      {
        "document": "Kymera R.pdf",
        "slide": 61
      },
      {
        "document": "Kymera R.pdf",
        "slide": 62
      },
      {
        "document": "Kymera R.pdf",
        "slide": 65
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-6",
    "targets": [
      "STAT6"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete STAT6 Degradation Selectivity in Human PBMC Proteosome at 100 x DC90",
      "Excellent Degradation Potency and Selectivity",
      "Picomolar Potency and Consistent Degradation Across all Disease-Relevant Cell Types Evaluated"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 19
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-579",
    "targets": [
      "Autoantibodies",
      "IFN\u03b2",
      "IFR5",
      "IL-12p40",
      "IL-1\u03b2",
      "IL-6",
      "IRF5",
      "TLR7",
      "TLR8",
      "TLR9",
      "TNF\u03b1",
      "Type-I IFN",
      "pro-inflammatory cytokines"
    ],
    "modalities": [
      "Oral Degrader",
      "oral degrader",
      "oral small molecule"
    ],
    "e3_ligases": [],
    "indications": [
      "IBD",
      "Lupus",
      "RA",
      "Rheumatoid Arthritis",
      "SLE",
      "Sjogren's disease",
      "Systemic Lupus Erythematosus",
      "Systemic Lupus Erythematosus (SLE)",
      "dermatomyositis",
      "lupus"
    ],
    "therapeutic_areas": [
      "Autoimmune Diseases",
      "I&I",
      "Immunology",
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1 HV"
    ],
    "claims": [
      "All KT-579 Treated Mice Survived Length of Study",
      "Clear reduction in IgG/complement glomeruli staining indicating reduced kidney disease involvement in SLE MRL/lpr mouse model with IRF5 degrader as compared to standard of care",
      "Completed non-GLP toxicity studies in NHP and rodents with no adverse effects at up to 200-fold predicted human efficacious exposure",
      "Degradation and selectivity",
      "Degrades all Cytoplasmic and Nuclear IRF5 (but not IRF3/7)",
      "Demonstrated Generally Better Outcomes than Approved or Clinically Active Drugs",
      "Effectively Blocks Circulating Cytokines In Mouse Model",
      "Effectively Blocks TLR Induced Pro-inflammatory Cytokines",
      "Excellent safety profile",
      "Inhibition of pro-inflammatory cytokines",
      "Inhibits IgG Levels After TLR9 Activation (CpG-B)",
      "Inhibits IgG production in SLE derived B cells",
      "KT-579 administered once daily for 63 days was well tolerated and prevented mortality more effectively than all other approved or clinically active comparator agents tested",
      "KT-579 blocks Type I IFN dependent genes at least as effectively as an anti-TLR7/8 drug (Afimetoran)",
      "KT-579 inhibits TLR7/8 induced ISGs that are associated with increased disease activity in SLE",
      "KT-579 led to sustained reduction of serum anti-dsDNA levels and reduction in splenic plasmablasts, differentiated B cells, and plasma cells, achieving effects comparable to, or better than, standard of care",
      "Leads to Significant Dose-dependent Inhibition of TLR7-R848 and TLR9-CpG-B Cytokine Production in Mouse",
      "Leads to Significant Reduction in Joint Swelling Comparable to Tofacitinib",
      "No adverse effects at up to 200-fold predicted human efficacious exposure",
      "Potently degrades IRF5",
      "Potently degrades IRF5 across multiple preclinical species with low oral doses",
      "Prevented disease associated mortality better than all other approved or clinically active agents tested",
      "Reduced proteinuria",
      "Reduces Joint Swelling",
      "Reduces TLR9 (CpG-B) induced plasmablast differentiation",
      "Reduces Total IgG levels in SLE PBMC Samples",
      "Results in significant reduction of circulating pro-inflammatory cytokines",
      "Results in significant reduction of pathogenic infiltrating T cells",
      "Selectively depletes TLR7/8 induced IRF5 nuclear translocation, while sparing IRF7 and IRF3",
      "Significant Reduction in Circulating Pro-inflammatory Cytokines",
      "Significantly Decreases IgG, Complement 3 (C3) and Renal Disease Progression",
      "Sustained Reduction of Serum Anti-dsDNA",
      "Type-I IFN inhibition",
      "best-in-class profile",
      "favorable safety profile",
      "first-in-class",
      "fully degrades IRF5",
      "highly selective",
      "potent",
      "selective",
      "well-tolerated"
    ],
    "safety": [
      "Completed non-GLP toxicity studies in NHP and rodents with no adverse effects",
      "Excellent safety profile",
      "de-risk safety",
      "favorable safety profile",
      "no AEs in non-GLP tox studies",
      "well-tolerated in safety studies up to 200-fold above the predicted human efficacious concentration"
    ],
    "evidence": [
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 26
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 27
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 28
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 34
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 35
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 36
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 37
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 38
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 39
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 40
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 41
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 42
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 43
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 44
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 45
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 47
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 48
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 49
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 37
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 42
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 43
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 44
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 45
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 46
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 48
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 49
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "IRF5 Degrader",
    "targets": [
      "IRF5"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "IB",
      "LE",
      "Lupus",
      "RA",
      "c1",
      "c2",
      "j\u00f6gren\u2019s"
    ],
    "therapeutic_areas": [
      "Autoimmune Diseases",
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Decreased Proteinuria",
      "Early, Sustained and Complete Reduction in Anti-dsDNA Abs",
      "Superior Activity Reducing Anti-dsDNA at Week 37"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 29
      },
      {
        "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
        "slide": 46
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 47
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-485",
    "targets": [
      "IRAK4"
    ],
    "modalities": [
      "degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "AD",
      "Asthma",
      "CAPS",
      "COPD",
      "Generalized Pustular Psoriasis",
      "Gout",
      "HS",
      "Macrophage Activation Syndrome",
      "RA",
      "RP"
    ],
    "therapeutic_areas": [
      "immune-inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "highly selective",
      "oral",
      "potent"
    ],
    "safety": [
      "absence of any QTc signal"
    ],
    "evidence": [
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 51
      },
      {
        "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
        "slide": 64
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "SAR444656",
    "targets": [
      "IRAK4"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 46
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-413",
    "targets": [
      "Aiolos",
      "IRAK1",
      "IRAK4",
      "Ikaros"
    ],
    "modalities": [
      "degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "1st line + SOC DLBCL",
      "MYD88 mutant R/R DLBCL",
      "MYD88 wild-type R/R DLBCL",
      "MYD88MT DLBCL",
      "PCNSL",
      "Primary CNS Lymphoma",
      "R/R B-cell NHL",
      "R/R B-cell lymphoma",
      "R/R DLBCL",
      "R/R MYD88mut DLBCL",
      "R/R MYD88mut DLBCL + SOC",
      "WM",
      "Waldenstrom\u2019s",
      "Waldenstr\u00f6m\u2019s Macroglobulinemia",
      "Wild Type DLBCL"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1a",
      "Phase 1b",
      "Phase 2",
      "Phase 3",
      "combinations",
      "monotherapy"
    ],
    "claims": [
      "40% KD of IRAK4 in blood",
      "At least 72h target degradation observed",
      "Complete Tumor Regressions",
      "Complete or partial regressions",
      "Extended tumor exposure",
      "First US Approval (Accelerated)",
      "Highly Active on Intermittent Dosing Regimens",
      "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with Rituxan",
      "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with the BCL-2 inhibitor, Venetoclax",
      "KT-413 administered on intermittent schedules leads to strong regressions in combination with the BTK inhibitor Ibrutinib",
      "More active in MYD88MT DLBCL cells than CC-220 and KTX-545",
      "PD Effects of KT-413",
      "PK Parameters of KT-413",
      "Potent Degrader of IRAK4 and IMiD Substrates",
      "Potential to be First Precision Medicine in DLBCL to Target a Genetically-defined Population",
      "Preliminary Clinical Activity (ORR, DoR, PFS, DCR, OS)",
      "Preliminary Estimates of Activity",
      "Profound antitumor effect in vitro and in vivo",
      "Safety/Tolerability and MTD and RP2D",
      "Safety/Tolerability at RP2D in Patients with DLBCL",
      "Second US Approval (Full)",
      "Strong antitumor activity",
      "Strong degradation of both IRAK4 and IMiD substrates",
      "Superior Anti-tumor activity",
      "Superior activity compared to IMiD CC-220",
      "Up to 95/100% KD of Ikaros/Aiolos"
    ],
    "safety": [
      "First 2 dose levels generally well-tolerated",
      "MTD/RP2D",
      "No DLTs",
      "No neutropenia observed",
      "No treatment-related SAEs",
      "safety",
      "tolerability"
    ],
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 49
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 52
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 53
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 54
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 55
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 56
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 57
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 17
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 18
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 22
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modalities": [
      "heterobifunctional degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "1st Line PTCL",
      "ALK+ ALCL",
      "Advanced solid tumors",
      "CTCL",
      "Cutaneous T-cell lymphoma (CTCL)",
      "LGL-L",
      "Large granular lymphocyte leukemia (LGL-L)",
      "PTCL",
      "Peripheral T-cell lymphoma (PTCL)",
      "R/R B-cell lymphoma",
      "Solid Tumor CRC MSI-H",
      "Solid Tumors",
      "Solid Tumors, PD-1 Combo (e.g. Stage IV MSI-H CRC)",
      "liquid tumor",
      "solid tumors",
      "\u22652nd Line R/R PTCL"
    ],
    "therapeutic_areas": [
      "CTCL",
      "Leukemia",
      "Lymphoma",
      "PTCL",
      "heme malignancies",
      "immuno-oncology",
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1a",
      "Phase 1b",
      "Phase 2",
      "Phase 3",
      "clinical development"
    ],
    "claims": [
      "10 mg/kg sufficient to drive full tumor regression in SU-DHL-1 that was durable for multiple weeks after the last dose",
      "Accelerated Approval",
      "At least 48h of target degradation observed",
      "Complete Tumor Regressions Associated with Robust STAT3 KD for \u223c48h in Preclinical Models",
      "First-in-class Opportunity",
      "Full Approval",
      "Highly Selective Degradation of STAT3",
      "Initial Proof-of-Mechanism demonstrated",
      "No dose-limiting toxicities observed to date",
      "PD Effects of KT-333",
      "PK Parameters of KT-333",
      "Preliminary Clinical Activity (ORR, DoR, PFS, DCR, OS)",
      "Preliminary Estimates of Activity",
      "Profound single agent activity",
      "Promising combo activity with anti-PD1",
      "STAT3 degradation consistent with preclinical predictions",
      "Safety/Tolerability and MTD and RP2D",
      "Safety/Tolerability at RP2D in Patients with Lymphoma/Leukemia and Solid Tumors",
      "Selective degradation of only STAT3 protein",
      "demonstrating PK/PD consistent with pre-clinical models"
    ],
    "safety": [
      "DL1 level generally well-tolerated with no DLTs or treatment-related SAEs",
      "Safety",
      "Tolerability"
    ],
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 58
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 61
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 64
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 65
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 66
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 6
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 7
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 8
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 9
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 10
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 13
      },
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 14
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KTX-201",
    "targets": [
      "STAT3"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "Immuno-Oncology"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "combination extends survival",
      "complete responders reject tumor rechallenge demonstrating development of long-term immune memory",
      "synergizes with anti-PD-1 leading to 60% complete responses"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 63
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "KT-253",
    "targets": [
      "MDM2",
      "PUMA",
      "p21",
      "p53"
    ],
    "modalities": [
      "degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "AML",
      "Liquid Tumors",
      "Solid Tumors",
      "Uveal melanoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "IND enabling"
    ],
    "claims": [
      "4 hr target coverage by KT-253 is sufficient to induce apoptosis",
      ">200-fold more potent in tumor cell killing assays than SMI's due to its mechanism of action",
      "Best-in-Class p53 Stabilizer",
      "Blocks the feedback loop which up-regulates MDM2 production",
      "Ensures high activity and improved therapeutic index vs SMI\u2019s",
      "Induces apoptosis in cell lines and in vivo xenografts",
      "Inhibits tumor cell growth with picomolar potency",
      "Intermittent dosing schedule of KT-253 can drive efficacy while increasing therapeutic index",
      "MDM2 Degradation (KT-253, 1 mg/kg) Leads to Fast Increase in p53, p21, and PUMA (Key Apoptotic Biomarker)",
      "More than 200-fold more potent than clinically active MDM2 small molecule inhibitors",
      "Potent MDM2 Degrader",
      "Potent MDM2 degrader",
      "Selective degradation of KT-253",
      "Single Dose of KT-253 Achieves Sustained Tumor Regression",
      "Single Dose of KT-253 Leads to Sustained Tumor Regression",
      "Strongly stabilizes p53",
      "Superior to MDM2/p53 Small Molecule Inhibitors",
      "Superior tumor cell killing (pM range)"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 75
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 78
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 79
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 80
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 81
      },
      {
        "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
        "slide": 84
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "IRAKIMiD (KT-413)",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 15
      }
    ]
  },
  {
    "company": "kymera",
    "program_name": "PF-06550833",
    "targets": [
      "IRAK4"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
        "slide": 25
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT7455",
    "targets": [
      "CRBN",
      "IKZF1",
      "IKZF3",
      "IRF-4"
    ],
    "modalities": [
      "MonoDAC Degrader",
      "MonoDAC\u00ae Degrader",
      "Monofunctional Degradation Activating Compound (MonoDAC)",
      "Small Molecule",
      "protein degrader",
      "small molecule"
    ],
    "e3_ligases": [
      "CRBN",
      "cereblon"
    ],
    "indications": [
      "Early Line MM",
      "Mantle Cell Lymphoma",
      "Multi-Refractory MM",
      "Multiple Myeloma",
      "Multiple myeloma",
      "Non-Hodgkin\u2019s Lymphoma",
      "Peripheral T-Cell Lymphoma",
      "Post-Transplant MM",
      "R/R MM",
      "R/R Multiple Myeloma",
      "R/R NHL",
      "Relapsed Refractory Multiple Myeloma",
      "Relapsed/Refractory Multiple Myeloma",
      "Relapsed/Refractory multiple myeloma",
      "Systemic Multiple Myeloma",
      "anaplastic large cell lymphoma",
      "multi-refractory MM patients",
      "multiple myeloma",
      "myeloma",
      "non-Hodgkin lymphoma",
      "non-Hodgkin\u2019s lymphoma",
      "peripheral T-cell lymphoma",
      "relapsed/refractory multiple myeloma",
      "relapsed/refractory non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [
      "Hematology",
      "Oncology",
      "multiple myeloma",
      "oncology"
    ],
    "clinical_phases": [
      "Discovery",
      "Monotherapy",
      "Phase 1",
      "Phase 1 dose escalation",
      "Phase 1 dose expansion",
      "Phase 1/2",
      "Phase 2",
      "Post-Transplant Maintenance Study",
      "Pre-clinical",
      "Registrational Study",
      "clinic",
      "first-in-human"
    ],
    "claims": [
      "48 hr Degradation Kinetics",
      ">1000-fold improvement in potency vs. Pomalidomide",
      "Accelerated Approval in Multi-Refractory MM",
      "Accumulation of drug was observed up to four-fold by day 15 (360 hours)",
      "Anti-myeloma activity and immunomodulatory effects observed at well tolerated doses",
      "Broad, potent antiproliferative activity in a panel of MM cell lines",
      "CFT7455 achieves equivalent efficacy at 1/100th of the dose compared to CC-92480",
      "CFT7455 is efficacious in MM models resistant or insensitive to IMiDs",
      "CFT7455 promotes regression in tumors insensitive to Pom",
      "CFT7455 results in durable tumor regressions in the NCI-H929 xenograft model",
      "CFT7455 retains activity in Len- & Pom-Resistant MM cells",
      "CFT7455 retains activity in Len- & Pom-resistant MM cells",
      "CFT7455 was rapidly absorbed, with a plasma half-life of approximately two days",
      "CFT7455 yields robust efficacy as monotherapy and in combination with dexamethasone",
      "Catalytic activity enhancement resulted in >1000-fold improvement in potency vs. Pom",
      "Cemsidomide + Dex demonstrated compelling anti-myeloma activity across a broad range of doses",
      "Cemsidomide is a novel, potent, cereblon-based IKZF1/3 MonoDAC\u00ae degrader",
      "Class-leading catalytic activity",
      "Class-leading catalytic activity to enable rapid and deep target degradation",
      "Deep IKZF3 degradation",
      "Deep IKZF3 degradation and regression in MM xenograft models",
      "Demonstrated Monotherapy Activity",
      "Demonstrates High Potency in MM Cell Lines and Xenografts",
      "Demonstrates anti-myeloma activity",
      "Demonstrates high potency in MM cell lines and xenografts",
      "Differentiated pharmacokinetic profile",
      "Durable Tumor PK",
      "Durable antitumor responses consistent with long-lived pharmacodynamic activity",
      "Durable single-agent activity",
      "Early and stable regression of disease",
      "Efficacy in models unresponsive to approved IMiDs",
      "Enhanced catalytic & pharmacologic properties",
      "Established Safety Profile and Dosing Schedule",
      "Excellent catalytic efficiency and enhanced PK profile leads to enhanced efficacy due to predictable suppression of IKZF1/3 between doses",
      "Expected efficacy and survival outcomes when combined with dexamethasone",
      "Has Broad Antiproliferative Activity",
      "Has broad antiproliferative activity",
      "High CRBN binding affinity (KD = 0.9 nM)",
      "High CRBN binding affinity (Kd = 0.9 nM)",
      "High binding affinity",
      "High binding affinity to overcome IMiD resistance",
      "High binding affinity to overcome low cereblon levels that drive resistance to lenalidomide and pomalidomide",
      "Highly Efficacious",
      "Highly Potent and Selective",
      "Immunomodulatory effects",
      "Improved pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation",
      "Linear, Durable Tumor PK",
      "Lower disease burden",
      "Maintenance Approval in Post-Transplant MM",
      "Metabolize through the liver to be better tolerated and potentially avoid kidney clearance",
      "Multiple patients achieved IMWG responses at low doses with best responses in patients refractory to BCMA therapies",
      "Numerous Approvals in Early Line MM",
      "Opportunity in combination with dexamethasone for multi-refractory patients",
      "Opportunity in combination with novel MM agents for early-line patients and as a maintenance therapy option",
      "Optimal 14 days on/14 days off schedule",
      "Optimized pharmacologic profile to enable sustained IKZF1/3 degradation",
      "Overcome resistance by maintaining efficacy at low cereblon levels",
      "Pharmacologic profile that enables sustained IKZF1/3 degradation",
      "Potent small molecule IKZF1/3 degrader",
      "Potent, rapid, and deep target degradation",
      "Predicted efficacious exposure (plasma 0.097 ng/mL)",
      "Promising Responses + Dexamethasone",
      "Promising Responses with CFT7455 + Dexamethasone",
      "Promotes Durable Tumor Regression",
      "Promotes durable tumor regression",
      "Rapid, deep degradation of IKZF1/3 that is associated with apoptosis",
      "Rapid, selective, and deep degradation of IKZF1/3 that is associated with apoptosis",
      "Reduce off-target toxicity and provide versatile combo potential",
      "Regression in MM xenograft models",
      "Regression in multiple treatment-na\u00efve MM tumor models at doses \u226510 \u00b5g/kg/day",
      "Regression in the treatment-na\u00efve H929 MM tumor models at doses \u226510 \u00b5g/kg/day",
      "Selective to reduce off-target liabilities",
      "Significant Potency Advantage over Other IKZF1/3 Degraders",
      "Significant improvement in survival with CFT7455 + dexamethasone combination",
      "Significant potency advantage over other IKZF1/3 degraders",
      "Single-agent efficacy in models unresponsive to approved IMiDs",
      "Sustained IKZF1/3 degradation",
      "The 50 \u00b5g dose achieved exposures which were active (and superior to pomalidomide) in pre-clinical models",
      "Well tolerated",
      "Well tolerated with no DLTs resulting in treatment discontinuations",
      "accumulation of drug up to 4-fold by day 15",
      "activity in CNS models of lymphoma",
      "demonstrates potent anti-tumor activity",
      "durable tumor regressions after drug discontinuation",
      "fast, selective degradation of IKZF1/3",
      "greater efficacy compared to pomalidomide",
      "increased activity in vivo compared to CC-92480",
      "manageable neutropenia",
      "meaningful decreases in dFLC",
      "potent CRBN binder",
      "potent tumor regression in IMiD-resistant multiple myeloma xenograft models",
      "promising efficacy signals",
      "sCR achieved in a pre-treated MM patient",
      "substantial potency and deeper degradation of IKZF1 and IKZF3",
      "sustained IKZF1/3 degradation",
      "synergistic activity with rituximab, ibrutinib, and romidepsin",
      "well absorbed with a plasma T1/2 of approximately 2 days",
      "well tolerated"
    ],
    "safety": [
      "2 DLTs",
      "2 DLTs occurred at 100 \u00b5g due to grade 4 thrombocytopenia",
      "3 patients with Grade 4 neutropenia",
      "38% of patients experienced Grade 3/4 neutropenia, which was manageable",
      "Acquired resistance to approved IKZF1/3 degraders",
      "Adverse event was a Grade 2 rash in the setting of early disease progression at the 50 \u03bcg dose on the MWF 14/14 schedule so there was limited benefit to continuing therapy",
      "Anemia",
      "CC-92480 is not detectable after 4 hours",
      "CFT7455 is well tolerated with no DLTs resulting in treatment discontinuations",
      "DLT associated with Grade 4 neutropenia >7 days",
      "DLT associated with febrile neutropenia",
      "Death was not related to CFT7455",
      "Determine the maximum tolerated doses",
      "High-risk MM, including extramedullary disease, remains difficult to treat",
      "Leukopenia",
      "Manageable neutropenia was the most common side effect",
      "Many MM/NHL therapies require onerous delivery (e.g., frequent dosing, IV administration)",
      "Modest on-target degradation and off-target liabilities",
      "Mouse missing in CFT7455 100 \u00b5g/kg group due to changes unrelated to treatment or disease",
      "Neutropenia",
      "No cases resulted in discontinuation or dose reductions",
      "Only 1 DLT occurred as of the data cutoff date",
      "Safety and tolerability",
      "Thrombocytopenia",
      "Well tolerated with no DLTs resulting in treatment discontinuations",
      "manageable neutropenia",
      "no DLTs resulted in discontinuations",
      "on-target neutropenia",
      "safety and tolerability of CFT7455 as monotherapy and in combination with dexamethasone",
      "well tolerated",
      "~50% of MM patients suffer from renal impairment, decreasing tolerability of renally cleared drugs"
    ],
    "evidence": [
      {
        "document": "CFT7455 ASH Trial-in-Progress Poster Presentation.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 3
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 11
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 12
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 13
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 14
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 15
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 16
      },
      {
        "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
        "slide": 17
      },
      {
        "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
        "slide": 10
      },
      {
        "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
        "slide": 20
      },
      {
        "document": "2023_ICML_Poster_CFT-7455_NHL-FINAL_approved (002).pdf",
        "slide": 1
      },
      {
        "document": "C4_2022_TPD_Summit_Final_v2.pdf",
        "slide": 10
      },
      {
        "document": "C4_2022_TPD_Summit_Final_v2.pdf",
        "slide": 17
      },
      {
        "document": "C4_2022_TPD_Summit_Final_v2.pdf",
        "slide": 18
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 1
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 7
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 8
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 9
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 10
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 11
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 12
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 13
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 15
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 16
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 17
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 18
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 22
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 23
      },
      {
        "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
        "slide": 24
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 1
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 8
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 12
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 14
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 16
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 17
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 18
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 19
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 20
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 21
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 27
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 28
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 29
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 32
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 33
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 34
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 36
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 37
      },
      {
        "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
        "slide": 38
      },
      {
        "document": "FINAL_CEMSIDOMIDE_POSTER_MM_11.13.24.pdf",
        "slide": 1
      },
      {
        "document": "AACR_Poster_Presentation_CFT7455_Phase_1_2_Cohort_A_Data.pdf",
        "slide": 1
      },
      {
        "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
        "slide": 6
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 1
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 5
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 6
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 7
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 8
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 9
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 10
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 11
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 12
      },
      {
        "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
        "slide": 13
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 3
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT1946",
    "targets": [
      "APC",
      "BRAF",
      "BRAF V600",
      "BRAF V600 Mutants",
      "BRAF V600E",
      "BRAF V600X",
      "BRAF-V600E",
      "BRAF-V600X",
      "MEK1",
      "MEK2",
      "Mutant BRAF",
      "NRAS",
      "NRAS-Q61K",
      "RNF43",
      "TERT",
      "TP53",
      "mBRAF"
    ],
    "modalities": [
      "BiDAC",
      "BiDAC degrader",
      "BiDACTM degrader",
      "BiDAC\u2122 degrader",
      "Degrader",
      "Selective Degrader",
      "degrader",
      "targeted protein degradation"
    ],
    "e3_ligases": [
      "CRBN",
      "cereblon"
    ],
    "indications": [
      "Advanced or Metastatic BRAF V600 Mutant Solid Tumors",
      "Anaplastic thyroid cancer (ATC)",
      "BRAF Driven Cancers",
      "BRAF V600 Mutant Solid Tumors",
      "BRAF V600 mutant driven solid tumors",
      "BRAF V600 mutant measurable solid tumors",
      "BRAF V600E Pancreatic Cancer",
      "BRAF V600E pancreatic carcinoma",
      "BRAF V600K melanoma",
      "BRAF-V600X\u2013driven cancers",
      "BRAF-driven Cancers",
      "CRC",
      "Colorectal cancer",
      "Colorectal cancer (CRC)",
      "Melanoma",
      "Non-small cell lung cancer",
      "Non-small cell lung cancer (NSCLC)",
      "Other Indications",
      "Solid Tumors",
      "anaplastic thyroid cancer (ATC)",
      "anaplastic thyroid carcinoma",
      "brain metastasis",
      "cholangiocarcinoma",
      "colorectal cancer",
      "colorectal cancer (CRC)",
      "inhibitor-resistant BRAF-V600X\u2013driven cancers",
      "melanoma",
      "non-V600X mBRAF Driven Cancers",
      "non-small cell lung cancer",
      "non-small cell lung cancer (NSCLC)",
      "pancreatic carcinoma",
      "small intestine cancer"
    ],
    "therapeutic_areas": [
      "Colorectal cancer",
      "Melanoma",
      "Non-small cell lung cancer",
      "Oncology",
      "mBRAF Class II and Class III driven cancers",
      "oncology"
    ],
    "clinical_phases": [
      "Ongoing",
      "Phase 1",
      "Phase 1/2",
      "Phase 1B",
      "Phase 1b",
      "Phase 2",
      "Phase I"
    ],
    "claims": [
      "8/11 melanoma patients demonstrated tumor reduction",
      "Active in BRAF-V600E/NRAS-Q61K, a model of clinical resistance to BRAF inhibitors",
      "Address failures in inhibitor-based therapy due to resistance mechanisms",
      "Addresses MAPK pathway alterations resulting from BRAF inhibitor resistance",
      "Anti-tumor activity seen across multiple BRAF V600 mutants",
      "Assess PK and PD",
      "Avoid paradoxical activation of RAF dimers",
      "Avoids paradoxical activation seen with approved inhibitors",
      "CFT1946 Degrades BRAF-V600E in a Dose Dependent Manner",
      "CFT1946 as a single agent and in combination with MEKi is effective in MAPK pathway inhibition, superior to BRAFi",
      "CFT1946 degrades BRAF V600E protein in all post-treatment biopsies to date",
      "CFT1946 degrades BRAF-V600E in a dose dependent manner",
      "CFT1946 provides proof of concept for degradation of selected non-V600E mBRAF of both Class II and Class III",
      "CFT1946 treatment demonstrates degradation of HA-tagged mBRAF in a dose-dependent manner",
      "CFT1946 treatment of Class III mBRAF model cell line shows proof of concept for TPD-mediated growth inhibition superior to BRAFi",
      "CFT1946 treatment of H1666 cells shows modest growth inhibition, superior to inhibition alone",
      "Causes BRAF-V600E Degradation",
      "Combination treatment of BRAFi resistant xenograft model with CFT1946 and MEKi shows tumor growth inhibition/regression",
      "Confirmed Partial Response",
      "Confirmed Partial Response in BRAF V600E Pancreatic Cancer",
      "Decrease in BRAF V600E allele fraction measured in ctDNA using WES",
      "Degradation of mutant BRAF protein overcomes resistance mechanisms",
      "Degraded BRAF V600E protein in all available post-treatment biopsies",
      "Determine RP2D/MTD",
      "Dose-dependent bioavailability",
      "Early Evidence of Anti-Tumor Activity",
      "Early evidence of monotherapy anti-tumor activity",
      "Early evidence of monotherapy anti-tumor activity in patients who progressed after treatment with BRAF inhibitors",
      "Effect deep elimination of mutant BRAF signaling and create durable responses",
      "Enables deep elimination of mutant BRAF signaling to create potential durable responses through degrader molecule recycling and catalytic effect",
      "Estimate anti-tumor activity",
      "HiBiT assay shows BRAF-V600E degradation with CFT1946 treatment in dose-dependent manner",
      "Increased drug exposure observed with dose escalation",
      "Intrinsic resistance in CRC patients supports CFT1946 in combination with cetuximab",
      "Loss of Viability in BRAF-V600E Cells",
      "Monotherapy anti-tumor activity in patients refractory to BRAF inhibitors",
      "No Grade \u2265 3 cutaneous adverse events commonly seen with wild-type BRAF inhibition",
      "No drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
      "Ongoing SD at 16.6 months",
      "Potent Inhibition of MAPK Signaling",
      "Potential to disrupt the treatment landscape and become an important option for patients",
      "Potentially deeper and more durable responses than BRAF inhibitors",
      "Prevent mutant BRAF-V600X incorporation into RAF dimers",
      "Prevents BRAF V600 mutant mono/heterodimer formation",
      "Proof of Degrader Concept",
      "Proof of Mechanism",
      "Proof of mechanism supported by BRAF V600E degradation",
      "Safety and tolerability",
      "Spares wild-type BRAF, likely avoiding AEs associated with inhibition of wild-type BRAF",
      "Specifically target mutant BRAF-V600X over wildtype BRAF",
      "Specifically targets BRAF V600 mutations, which includes BRAF V600 mutations beyond BRAF V600E",
      "Specifically targets BRAF V600X mutations, which includes BRAF V600 mutations beyond BRAF V600E",
      "Subject had confirmed PR after data cut off",
      "Tumor reduction in 16/27 patients",
      "Tumor reductions observed in patients with various V600 mutation types",
      "Well tolerated and highly selective degrader",
      "Well tolerated safety profile in an advanced and metastatic patient population",
      "abrogates resistance and paradoxical activation associated with RAF dimerization",
      "degradation of BRAF V600E protein",
      "demonstrates efficacy in multiple models of BRAF V600X-driven cancers",
      "evidence of anti-tumor activity",
      "increased drug exposure with dose escalation",
      "pERK loss aligns with loss of BRAF-V600E protein demonstrating MAPK pathway inhibition",
      "potent and mutant-selective",
      "preliminary proof of mechanism",
      "superior activity to clinically approved BRAF inhibitors",
      "superior to inhibitors in in vitro and in vivo models",
      "well-tolerated safety profile"
    ],
    "safety": [
      "Likely avoiding AEs associated with inhibition of wild-type BRAF",
      "Majority of TEAEs observed were mild to moderate",
      "No DLTs",
      "No Grade > 3 treatment-related cutaneous adverse events",
      "No Grade \u2265 3 cutaneous adverse events",
      "No new primary malignancies",
      "No treatment-related SAEs",
      "Safety and tolerability",
      "likely avoiding AEs associated with inhibition of wild-type BRAF",
      "no Grade \u22653 wild-type adverse events common to BRAFi",
      "no drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
      "only one Grade \u22653 treatment-related adverse event"
    ],
    "evidence": [
      {
        "document": "C4_356a_ASCO_2023_Trial_in_progress_poster.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 5
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 6
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 7
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 8
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 9
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 10
      },
      {
        "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
        "slide": 11
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 1
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 3
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 5
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 6
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 7
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 8
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 9
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 14
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 16
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 18
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 19
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 20
      },
      {
        "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
        "slide": 21
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 1
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 3
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 8
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 10
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 11
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 14
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 16
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 18
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 20
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 21
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 22
      },
      {
        "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
        "slide": 23
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 1
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 3
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 4
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 5
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 6
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 7
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 8
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 9
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 10
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 11
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 13
      },
      {
        "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
        "slide": 14
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 4
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 9
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 10
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 11
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 12
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 13
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 14
      },
      {
        "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
        "slide": 15
      },
      {
        "document": "C4_2024_AACR_CFT1946 _FINAL.pdf",
        "slide": 1
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT8919",
    "targets": [
      "CCND1",
      "EGFR",
      "EGFR C797S",
      "EGFR Exon 21 Mutants",
      "EGFR L858R",
      "EGFR-L858R",
      "EGFR-L858R-T790M",
      "EGFR-L861Q"
    ],
    "modalities": [
      "Allosteric Degrader",
      "Oral, Allosteric, Mutant-selective Degrader",
      "Oral, CNS-Active, Allosteric Degrader",
      "oral",
      "selective, allosteric degrader",
      "targeted protein degradation"
    ],
    "e3_ligases": [],
    "indications": [
      "EGFR inhibitor-resistant non-small cell lung cancer",
      "EGFR patients who develop resistance to osimertinib",
      "NSCLC",
      "Non-Small Cell Lung Cancer",
      "Non-small cell lung cancer",
      "brain metastases"
    ],
    "therapeutic_areas": [
      "Oncology",
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "25-45% of mutant EGFR NSCLC is driven by L858R activating mutation; these patients are not adequately addressed with current EGFR therapies",
      "Active in vitro and in vivo in models with secondary EGFR mutations",
      "Active in vitro and in vivo in models with secondary mutations",
      "Clinical evaluation is warranted",
      "Demonstrates intracranial activity",
      "Demonstrates intracranial activity indicating potential to prevent or treat brain metastases in patients with EGFR L858R-driven tumors",
      "Does not hit wild-type, potentially resulting in better tolerability",
      "May combine with approved EGFR inhibitors",
      "Not impacted by EGFR T790M or C797S",
      "Orally bioavailable, selective, allosteric degrader of EGFR L858R",
      "Potent and selective against L858R regardless of secondary mutations",
      "Potential for single agent activity in the front-line setting",
      "Potential to be active as single agent in the frontline setting",
      "Potential to prevent or treat brain metastases",
      "Pre-clinical data suggests CFT8919 has path to registration in EGFR patients who develop resistance to osimertinib",
      "Selectively targets EGFR-L858R in human cancer cell lines"
    ],
    "safety": [
      "Toxicities associated with inhibition of wild-type EGFR limit tolerability"
    ],
    "evidence": [
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 20
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 21
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 23
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 24
      },
      {
        "document": "2026 January Deck_FINAL_1.18.26.pdf",
        "slide": 25
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 4
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 7
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 10
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 11
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 12
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 14
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 15
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 16
      },
      {
        "document": "CFT8919_Pre_Clinical_Data.pdf",
        "slide": 17
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 1
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 6
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 7
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 8
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 9
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 10
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 11
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 13
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 14
      },
      {
        "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
        "slide": 15
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT8634",
    "targets": [
      "BRD9"
    ],
    "modalities": [
      "BiDAC degrader",
      "BiDAC\u2122 degrader",
      "bifunctional degradation activating compound"
    ],
    "e3_ligases": [
      "cereblon"
    ],
    "indications": [
      "SMARCB1-Perturbed Cancers",
      "SMARCB1-null solid tumors",
      "SMARCB1-null tumors",
      "Synovial Sarcoma",
      "synovial sarcoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1/2",
      "Phase 2"
    ],
    "claims": [
      "CFT8634 demonstrated a manageable safety profile",
      "CFT8634 has shown preliminary evidence of anti-tumor activity",
      "CFT8634 is an orally bioavailable selective bifunctional degrader of BRD9",
      "orally bioavailable",
      "potent",
      "selective"
    ],
    "safety": [
      "Frequency and severity of AEs and SAEs of CFT8634",
      "Majority of AEs reported were considered mild to moderate in severity",
      "No clear dose dependent relationship to incidence/severity of TEAEs was observed"
    ],
    "evidence": [
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 1
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 10
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 11
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 14
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 15
      },
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 17
      },
      {
        "document": "C4_2206598_CTOS 2022_Final.pdf",
        "slide": 1
      },
      {
        "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
        "slide": 28
      },
      {
        "document": "CFT8634-CTOS 2023 Poster_Final_11.1.23[3].pdf",
        "slide": 1
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "CFT-8634",
    "targets": [
      "BRD9"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
        "slide": 12
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "Compound 27",
    "targets": [
      "BRD9"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "Synovial Sarcoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degrades Endogenous BRD9",
      "Inhibits Synovial Sarcoma Cell Growth"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
        "slide": 25
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "Cemsidomide (CFT7455)",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modalities": [
      "MonoDAC\u00ae Degrader",
      "MonoDAC\u00ae degrader"
    ],
    "e3_ligases": [
      "cereblon"
    ],
    "indications": [
      "Relapsed/Refractory Multiple Myeloma",
      "multiple myeloma",
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Catalytic activity enabling rapid and deep target degradation",
      "High binding affinity to overcome resistance due to low cereblon levels",
      "Pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation",
      "catalytic activity enabling rapid and deep target degradation",
      "high binding affinity to overcome resistance due to low cereblon levels",
      "pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation"
    ],
    "safety": [
      "On-target neutropenia",
      "on-target neutropenia"
    ],
    "evidence": [
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 1
      },
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 3
      },
      {
        "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
        "slide": 2
      }
    ]
  },
  {
    "company": "c4_therapeutics",
    "program_name": "Cemsidomide 14/14 + Dex",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-471",
    "targets": [
      "ER",
      "ESR1",
      "ESR1 mutant",
      "ESR1 wild-type",
      "Estrogen Receptor",
      "Estrogen receptor",
      "LRRK2",
      "Target 1",
      "Target 2",
      "estrogen receptor"
    ],
    "modalities": [
      "PROTAC",
      "oral, high-potency ER degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "1L ER+ breast cancer",
      "2L+ ER+/HER2- mBC",
      "ER+ Breast Cancer",
      "ER+ and HER2- advanced breast cancer",
      "ER+ breast cancer",
      "ER+ locally advanced or metastatic breast cancer",
      "ER+ metastatic breast cancer",
      "ER+/HER2- Breast Cancer",
      "ER+/HER2- advanced breast cancer",
      "ER+/HER2- breast cancer",
      "ER+/HER2\u2010 advanced breast cancer",
      "ER-positive breast cancer",
      "Neurodegenerative Disorders",
      "Prostate Cancer",
      "Solid and Haematological Malignancies",
      "advanced breast cancer",
      "breast cancer",
      "locally advanced breast cancer",
      "metastatic breast cancer",
      "metastatic castrate-resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "Breast Cancer",
      "Hematology",
      "Neurodegenerative Disorders",
      "Neuroscience",
      "Oncology",
      "breast cancer",
      "oncology"
    ],
    "clinical_phases": [
      "1L",
      "2L",
      "3L",
      "Ph1B",
      "Ph2",
      "Ph3",
      "Phase 1",
      "Phase 1/1b",
      "Phase 1b",
      "Phase 2",
      "Phase 3",
      "Preclinical",
      "clinical trial"
    ],
    "claims": [
      "68% Reduction in ER after treatment with 60 mg ARV-471",
      "80% of breast cancers are estrogen receptor (ER) positive",
      "89% of TRAEs were grade 1/2 in severity with no DLTs",
      ">85% LRRK2 degradation in deep brain regions of cynomolgus monkeys after oral dosing",
      "ARV-471 degrades ESR1mut and ESR1wt equally",
      "ARV-471 demonstrates promising anti-tumor activity in late-line patients",
      "ARV-471 has been well tolerated",
      "ARV-471 has the potential to be a best-in-class ER-directed therapy",
      "Achieved significant tumor shrinkage in combination with palbociclib (131% TGI) in an MCF-7 xenograft mouse model",
      "Begin early breast cancer study (neoadjuvant setting)",
      "Better ER degradation than fulvestrant",
      "Clinical Benefit Rate: 38% (All patients), 51% (Patients with ESR1 mutant tumors)",
      "Compelling efficacy signal in heavily pretreated patients",
      "Confirmed RECIST Partial Response in a patient with extensive prior therapy and an ESR1 mutation at 120 mg",
      "Continued efficacy and favorable tolerability",
      "Degradation exceeds reported data for fulvestrant",
      "Degradation superior to fulvestrant",
      "Degradation up to 89%",
      "Degraded ER up to 90%",
      "Designed to be an oral, high-potency ER degrader with favorable safety profile",
      "ER degradation up to 89% continues to exceed reported degradation in fulvestrant and clinical-stage SERDs",
      "Excellent tolerability and signals of efficacy in the most heavily pretreated patients of any ER-targeting therapy",
      "Favorable tolerability at both 200 mg qd and 500 mg qd",
      "Favorable tolerability profile at 200 and 500 mg qd",
      "First-in-class ER-degrading PROTAC",
      "Fulvestrant has demonstrated the value of ER degradation in breast cancer",
      "In 35 patients treated at 200mg (RP3D), no dose reductions and only 1 discontinuation",
      "In all 10 mice in experiment, tumors reduced by >80%",
      "In corresponding quantitative western blots, ER is reduced by 79% and 88% in the 10 mpk and 30 mpk arms, respectively, vs. 63% for fulvestrant",
      "Initiate Phase 1b combination study with everolimus",
      "Mean ER degradation was 71%",
      "Median ER degradation was 69%",
      "No signal for bradycardia or visual disturbance",
      "No single TRAE in more than ~20% of patients",
      "Oral, daily dose of ARV-471 inhibited tumor growth by 99% at 10 mpk and 106% at 30 mpk in an ESR1 mutant PDX model",
      "Outstanding tolerability profile",
      "Planned combinations with CDK4/6 inhibitors in adjuvant or early metastatic cancers",
      "Potential best-in-class estrogen receptor-targeting therapy",
      "Potential for 2L/3L approval as monotherapy or in combination",
      "Potential to be the endocrine backbone of choice for ER+/HER2- breast cancer treatment",
      "Progression-Free Survival: 3.7 Months (All patients), 5.7 Months (Patients with ESR1 mutant tumors)",
      "Robust signals of efficacy",
      "Share completed Phase 1 data",
      "Strong CBR and mPFS in heavily treatment-resistant patients",
      "Strong efficacy signal in a predominantly ER-independent population",
      "Superior ER degradation compared to SERDs",
      "Superior degradation to fulvestrant and SERDs",
      "Superior degradation to published fulvestrant and SERD data",
      "Superior inhibitor of tumor growth compared to fulvestrant",
      "Superior tumor growth inhibition versus fulvestrant in a Y537S (ER gene mutation) PDX model",
      "Superior tumor shrinkage (in combination with palbociclib) compared to fulvestrant (108% TGI)",
      "Well tolerated",
      "Well tolerated, with manageable adverse events",
      "average degradation of 62%",
      "best-in-class ER-targeting therapy",
      "best-in-class estrogen receptor-targeting therapy",
      "clinical benefit rate (CBR) of 40%",
      "clinical benefit rate of 40% (19 of 47 evaluable patients)",
      "clinical benefit rate of 42% (5 of 12 evaluable patients)",
      "complete ER antagonist",
      "confirmed partial responses",
      "degraded ER up to 90% through the 120 mg dose level",
      "demonstrated safety and efficacy in men with late-line metastatic castrate-resistant prostate cancer",
      "demonstrated signals of efficacy in both ESR1 mutant and wild-type patients",
      "demonstrated strong signals of efficacy in the VERITAC Phase 2 trial",
      "dose-proportional pharmacokinetics",
      "early clinical benefit",
      "early evidence of ER degradation",
      "fast-to-market strategy",
      "first-in-class",
      "maximum ER degradation of 89%",
      "mean of 64%",
      "median 67%",
      "no DLTs; dose escalation continues",
      "oral, best-in-class ER-directed therapy",
      "potent degrader of ER",
      "potential first- and best-in-class ER degrader",
      "potential to degrade ER better than fulvestrant",
      "promising efficacy and tolerability profile",
      "robust signals of efficacy",
      "superior ER degradation (>90%)",
      "superior ER degradation and tumor inhibition in preclinical studies",
      "superior tumor regression versus fulvestrant",
      "validated PROTAC protein degrader"
    ],
    "safety": [
      "ALT increased (n=1)",
      "Back pain/spinal cord compression (n=1)",
      "Bradycardia",
      "Diarrhea",
      "Discontinuation rate <2% (1 out of 60)",
      "Dose reductions <2% (1 out of 60)",
      "ECG T-wave abnormality (n=1)",
      "Fatigue (n=1)",
      "Four patients experienced Gr 3 events potentially related to ARV-471 (headache lasting 1-day, single occurrence of asymptomatic increased amylase and lipase, nausea and asymptomatic QTc prolongation, and venous embolism after a minor procedure)",
      "Grade 3/4 TRAE reported in 6% (2/35) patients at 200 mg",
      "In 35 patients treated at the recommended Phase 3 dose (200 mg), no dose reduction and 1 discontinuation",
      "Its safety and effectiveness have not been established.",
      "MTD not reached",
      "Majority (89%) of AEs reported were grade 1/2",
      "Maximum Tolerated Dose/Recommended Phase 2 Dose/Safety",
      "Nausea",
      "Neutropenia (n=1)",
      "No dose limiting toxicities",
      "No dose reductions and one discontinuation at 200 mg phase 3 dose",
      "No treatment-related AEs or DLTs were observed in the first cohort of ARV-471",
      "Outstanding tolerability profile observed",
      "QT prolongation (n=1)",
      "Visual disturbance",
      "Vomiting",
      "Well tolerated",
      "Well tolerated at all dose levels",
      "Well tolerated, with manageable adverse events",
      "Well-tolerated across all dose levels with no dose limiting toxicities up to 700mg",
      "adverse events were primarily Grade 1",
      "favorable safety profile",
      "favorable tolerability profile",
      "no DLTs",
      "no Grade 3 adverse events",
      "no dose limiting toxicities",
      "well tolerated at all dose levels"
    ],
    "evidence": [
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 5
      },
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 6
      },
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 7
      },
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 8
      },
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 9
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 1
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 2
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 3
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 4
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 5
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 6
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 7
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 9
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 10
      },
      {
        "document": "ARV-471 Collaboration Presentation_vF.pdf",
        "slide": 12
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 6
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 7
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 8
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 9
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 11
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 12
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 13
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 14
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 15
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 18
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 19
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 20
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 22
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 59
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 9
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 10
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 11
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 12
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 13
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 20
      },
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 13
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 13
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 14
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 15
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 16
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 17
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 33
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 1
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 2
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 3
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 4
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 5
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 6
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 8
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 9
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 11
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 12
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 13
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 14
      },
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 15
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 1
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 2
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 4
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 5
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 6
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 7
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 8
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 13
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 14
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 16
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 17
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 19
      },
      {
        "document": "SABCS IR deck December 8 2022.pdf",
        "slide": 20
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 4
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 11
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "BCL6 PROTAC\u00ae degrader",
    "targets": [
      "BCL6"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "Diffuse Large B-Cell Lymphoma (DLBCL)"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "first-in-class potential therapy"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 15
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "BCL-057",
    "targets": [
      "BCL6"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [
      "Diffuse Large B-Cell Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "GLP toxicity studies"
    ],
    "claims": [
      "Complete tumor stasis at low, oral daily doses",
      "Tumor stasis correlates with 95-100% degradation of measurable BCL6",
      "inhibits tumor growth by nearly 100%"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "JPM Presentation_Final_01.11.23.pdf",
        "slide": 16
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-110",
    "targets": [
      "AR",
      "Androgen Receptor",
      "F877L",
      "H875Y",
      "M895V",
      "T878A",
      "androgen receptor"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [
      "CSPC",
      "early-line mCRPC",
      "late-line mCRPC",
      "mCRPC",
      "mCSPC",
      "men with mCRPC",
      "metastatic castrate resistant prostate cancer",
      "metastatic castration-resistant prostate cancer",
      "molecularly defined, late-line mCRPC",
      "prostate cancer",
      "refractory mCRPC"
    ],
    "therapeutic_areas": [
      "oncology",
      "prostate cancer"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3",
      "clinical stage"
    ],
    "claims": [
      "10 mpk ARV-110: 70% tumor growth inhibition",
      "40% PSA50 in a molecularly defined subgroup",
      "AR degradation and late-line activity suggest strong potential across multiple disease states",
      "AR molecular profiling identifies a molecularly defined, late line population that may offer a possible path to accelerated approval",
      "ARV-110 demonstrates efficacy and plasma PSA reduction in an enzalutamide-insensitive patient derived xenograft model",
      "ARV-110 has shown clinical benefit in Phase 1 in a highly refractory patient population",
      "ARV-110 inhibits tumor growth in an in vivo model of acquired enzalutamide resistance",
      "ARV-110 is well tolerated, allowing continued dose escalation up to 700 mg daily",
      "ARV-110 is well tolerated, allowing continued dose escalation up to current dose of 700 mg daily, and potentially supporting use in earlier lines of therapy",
      "Accelerated approval in molecularly defined mCRPC",
      "Activity in wild-type AR patients supports broader use",
      "Anti-Tumor Activity (PSA, RECIST)",
      "Best PSA Change In Patients with Wild-Type AR (N=15)",
      "Biomarkers",
      "Broader 1L/2L mCRPC",
      "Confirmed RECIST partial response in a patient with a PCWG3",
      "Daily and orally delivered ARV-110 significantly inhibited tumor growth",
      "Degrades >90% AR protein in vivo",
      "Driving tumor responses and PSA reductions",
      "Duration of ARV\u2010110: 18 weeks and ongoing",
      "High unmet need across all stages of prostate cancer",
      "In vivo activity in multiple xenograft models",
      "Maximum Tolerated Dose/Recommended Phase 2 Dose/Safety",
      "Near complete regression of adenopathy after 4 cycles",
      "Orally delivered ARV-110 significantly inhibited tumor growth in these intrinsically enza-insensitive tumors (TGI: 100%)",
      "PSA reduction is associated with plasma exposure",
      "PSA50 13% (2/15)",
      "PSA: 97% decline",
      "Pharmacokinetics",
      "Plasma PSA levels following ARV-110 treatment significantly decreased vs. mice treated with vehicle or enzalutamide",
      "Potential for accelerated approval",
      "Preclinical profile translating into clinical benefit",
      "Promising antitumor activity in heavily pre-treated patients with limited treatment options",
      "Proves the concept of PROTAC targeted protein degradation, validating our confidence in our pipeline of degraders",
      "Proving the concept of PROTAC protein degradation",
      "RECIST: 80% reduction in tumor measurements",
      "Robust signals of efficacy",
      "Signals of efficacy in a heavily pretreated patient population with high unmet need, where traditional inhibitors have failed",
      "Two potential registrational paths",
      "Well tolerated",
      "clear initial efficacy signal in dose escalation",
      "degrades AR in tumor tissue",
      "early clinical proof-of-concept (safety, AR degradation, efficacy) demonstrated",
      "encouraging efficacy signals",
      "first PROTAC degrader with an efficacy signal in humans",
      "first evidence for androgen receptor degradation in patients",
      "first proof of mechanism for PROTAC\u00ae protein degraders",
      "highly selective degradation of AR",
      "manageable tolerability",
      "may overcome point mutations and other drivers of resistance",
      "overcomes known resistance mechanisms to enzalutamide and abiraterone",
      "overcomes mechanisms of resistance to current standards of care",
      "planned registrational path aligns with unmet need",
      "potential best-in-class therapy",
      "potential label expansion into earlier settings",
      "potential path to accelerated approval",
      "potential to address unmet patient need in 1L mCRPC and mCSPC",
      "potentially first- and best-in-class AR-targeted therapy",
      "safety profile acceptable for potential use in frontline settings",
      "selectively degrades AR",
      "showing early clinical benefit in highly refractory patients",
      "substantially exceeded expectations for PSA50 responses",
      "suggests potential for accelerated approval",
      "suggests potential in early prostate cancer",
      "well tolerated"
    ],
    "safety": [
      "6 patients on other statins, including 3 on atorvastatin (Lipitor\u00ae) and no ALT/AST adverse events",
      "ARV-110 is not blood-brain barrier penetrant",
      "Does not degrade L702H or AR-V7",
      "Dose increases dependent on toxicities: range 25% (if 1 DLT in 6 pts) to 100% (\u2264Grade 1 Adverse Events)",
      "First patient with DLT: Grade 3/4 ALT/AST and renal failure",
      "Following introduction of rosuvastatin restriction, no further elevation in LFTs observed",
      "Low rates of discontinuation or dose reduction from the RP2D due to TRAEs",
      "No DLTs",
      "No dose limiting toxicities (DLTs)",
      "No grade 2/3/4 treatment related AEs",
      "No treatment related Adverse Events (AEs)",
      "Patient continues on ARV\u2010110 with no further toxicity",
      "Safety cut-off date: October 2, 2020",
      "Second patient with Grade 3 ALT/AST; re\u2010challenge off rosuvastatin supported contribution of rosuvastatin",
      "The majority of TRAEs are Grade 1 or 2",
      "Well tolerated",
      "dose escalation continues",
      "early clinical safety data presented",
      "escalating through the current dose of 700 mg",
      "favorable safety profile observed in the first 3 cohorts",
      "generally well tolerated",
      "initial safety/pharmacokinetic data shared Oct. 2019",
      "no Grade \u22654 TRAEs",
      "well tolerated"
    ],
    "evidence": [
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 1
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 3
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 4
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 6
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 8
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 9
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 11
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 12
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 14
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 15
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 16
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 17
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 19
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 20
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 21
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 22
      },
      {
        "document": "ARVN ASCO 2020_VF.pdf",
        "slide": 26
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 23
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 24
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 26
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 27
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 28
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 29
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 31
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 32
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 34
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 36
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 37
      },
      {
        "document": "ARVN_Clinical Program Update ARV-110 .pdf",
        "slide": 38
      },
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 1
      },
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 3
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 14
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 15
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 16
      },
      {
        "document": "2021 TPD Summit - Arvinas Presentation.pdf",
        "slide": 17
      },
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 11
      },
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 12
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 1
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 8
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 9
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 10
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 11
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 12
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 31
      },
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 32
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "bavdegalutamide (ARV-110)",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 2
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "AR T878X/H875Y",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "6 of 7 patients had tumor reductions",
      "Activity was durable; patients with confirmed partial responses (PR) remained on treatment for approximately 9 (ongoing) and 10 months",
      "Durable partial responses in 2 of 7 RECIST-evaluable patients"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 14
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "AR T878X/875Y",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "46% PSA50 rate",
      "Durable partial responses",
      "Tumor regression"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
        "slide": 15
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-102",
    "targets": [
      "C1QTNF1",
      "CD68",
      "CTSH",
      "Cathepsin B",
      "ENTPD1",
      "GPNMB",
      "GRN",
      "IBA1",
      "LRRK2",
      "TMEM106A"
    ],
    "modalities": [
      "PROTAC",
      "PROTAC\u00ae Degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "PSP",
      "Parkinson's",
      "Parkinson's disease",
      "Parkinson\u2019s",
      "Parkinson\u2019s disease",
      "neurodegeneration",
      "neurodegenerative disease",
      "progressive supranuclear palsy"
    ],
    "therapeutic_areas": [
      "Neurology",
      "Parkinson\u2019s disease",
      "neurodegenerative diseases"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "clinical",
      "preclinical"
    ],
    "claims": [
      "50x greater pathway engagement with ARV-102",
      "50x greater target engagement with ARV-102",
      ">50% decreases in phospho-Rab10T73 and BMP in urine",
      "ARV-102 degrades LRRK2 in NHP deep-brain regions",
      "ARV-102 induced dose-dependent reductions in LRRK2 levels in CSF, with >50% LRRK2 reduction at single doses \u226560 mg and repeated doses \u226520 mg",
      "CSF levels of LRRK2 track cortex LRRK2",
      "Cathepsin B is reduced by ARV-102",
      "Decreased LRRK2 protein levels in PBMCs after a single oral dose",
      "Dose-dependently increased degradation efficiency and lysosome number vs kinase inhibitors",
      "Enrollment complete",
      "Final data from HV SAD/MAD cohorts presented at MDS",
      "First-in-human data presented during oral presentation at AD/PD",
      "GPNMB is reduced by ARV-102",
      "IBA1 is reduced by ARV-102",
      "Increases lysosome degradation in A549 cells",
      "Increases lysosome functional degradative capacity and number in cells",
      "Increases lysosome number in A549 cells",
      "Investigational compound. Its safety and effectiveness have not been established.",
      "Orally dosed ARV-102 reaches multiple deep brain regions in NHPs and degrades LRRK2 up to 94%",
      "Potential for oral therapies",
      "Potential to cross the blood brain barrier and degrade disease-causing proteins inside cells",
      "Presenting initial single ascending dose data",
      "Putative LRRK2 biomarkers associated with disease are reduced in non-human primate CSF after dosing with ARV-102",
      "Specifically target pathogenic proteins in the brain",
      "better target engagement",
      "dose-dependent increases in LRRK2 reductions in CSF indicate brain penetration and target engagement",
      "dose-dependent increases in exposure in cerebral spinal fluid after single and multiple doses indicated brain penetration",
      "enhanced potency",
      "normalization of cytokine and purinergic signaling",
      "pathway engagement versus a LRRK2 inhibitor",
      "reduced lysosomal markers reflecting effects on proteolysis, lysosomal integrity, and microglial activation",
      "reductions in downstream LRRK2 pathway biomarkers in blood cells and urine",
      "significant reductions in lysosomal pathway markers"
    ],
    "safety": [
      "Safety",
      "Tolerability"
    ],
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 11
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 13
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 17
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 19
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 20
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 22
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 23
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 24
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 25
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 26
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 27
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 28
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 1
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 5
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 14
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-027",
    "targets": [
      "polyQ-AR"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [
      "spinal bulbar muscular atrophy"
    ],
    "therapeutic_areas": [
      "Neurology"
    ],
    "clinical_phases": [],
    "claims": [
      "induced polyQ-AR degradation in muscle tissues",
      "rescued strength and endurance"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 29
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 32
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 33
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-393",
    "targets": [
      "BCL6",
      "CDKN1B",
      "IRF4",
      "PTPN6"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [
      "DLBCL",
      "Diffuse Large B-Cell Lymphoma",
      "T-cell lymphoma",
      "diffuse large B-cell lymphoma",
      "nTFHL-AI",
      "non-Hodgkin lymphoma",
      "relapsed/refractory mature B-cell NHL",
      "relapsed/refractory non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [
      "Hematology-Oncology",
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "preclinical"
    ],
    "claims": [
      "ARV-393 rapidly degrades >90% of BCL6 within 2 hours",
      "Broad combinability with complete tumor regressions in combination with SOC biologics and investigational small molecule agents",
      "Demonstrated significant anti-tumor single-agent activity",
      "Potent, orally bioavailable PROTAC small molecule degrader of BCL6",
      "breadth of efficacy beyond DLBCL demonstrated in multiple patient-derived xenograft (PDX) models with no body weight loss",
      "degradation is mediated by PROTAC mechanism",
      "demonstrated >90% TGI",
      "demonstrates activity in combination with SOC chemotherapy/biologics",
      "demonstrates activity in combination with small molecule inhibitors",
      "drives tumor regressions, including complete responses",
      "drives tumor regressions, including complete responses, in preclinical models",
      "evidence of significant efficacy comparable to SOC romidepsin",
      "exhibits picomolar degradation potency",
      "induces dose-dependent and sustained tumor growth inhibition",
      "induces tumor growth inhibition in PDX models of various non-Hodgkin lymphoma subtypes",
      "investigational compound",
      "no adverse impact on animal health/body weight",
      "overcomes BCL6 high resynthesis rate",
      "potential to be an attractive combination partner for development of novel treatment options",
      "potently degrades BCL6",
      "safety and effectiveness have not been established",
      "tumor regression at 30 mg/kg dosed once per day"
    ],
    "safety": [
      "no body weight loss"
    ],
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 34
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 37
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 38
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 39
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 40
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 41
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 42
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 43
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 44
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 45
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 46
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 47
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [
      "Colorectal Cancer",
      "KRAS G12D mutated advanced solid tumors",
      "Pancreatic Cancer",
      "colorectal cancer",
      "non-small cell lung cancer",
      "pancreatic cancer",
      "previously treated KRAS G12D mutated advanced PDAC"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      ">25-fold greater potency in reducing cancer cell proliferation compared with clinical-stage KRAS G12D ON and OFF inhibitors and a clinical-stage G12D degrader",
      ">25-fold more potent than all G12D-targeting competitors",
      ">40-fold higher potency in degrading KRAS G12D protein vs the comparable clinical-stage G12D degrader",
      ">40-fold more potent than KRAS G12D levels",
      "ARV-806 degrades KRAS G12D with picomolar potency",
      "ARV-806 demonstrates exquisite selectivity for KRAS G12D, indicating a robust therapeutic index",
      "ARV-806 effectively eliminates KRAS G12D from cancer cells",
      "ARV-806 forms a ternary complex with both OFF (GDP-bound) and ON (GTP-bound) KRAS G12D",
      "ARV-806 is a highly potent, selective degrader of KRAS G12D",
      "ARV-806 is selective for KRAS G12D",
      "ARV-806 treatment directly leads to ubiquitination of KRAS G12D protein",
      "Catalytic activity (overcomes upregulation, a common mechanism of resistance to inhibitor treatment)",
      "Demonstrates anti-proliferative activity approximately 25 times greater than KRAS inhibitors and the leading clinical-stage degrader",
      "Investigational compound. Safety and effectiveness have not been established.",
      "KRAS G12D reduced >90% for 7 days",
      "Proliferative marker (c-MYC) suppressed and pro-apoptotic marker (BIM) increased for 5 days",
      "Targeting both OFF and ON KRAS G12D allows ARV-806 to eliminate this oncogenic protein from the cell",
      "leads to robust and extended degradation and signaling suppression in vivo",
      "more potently increases apoptosis (cell death)",
      "more potently induces pancreatic cancer cell death in vitro relative to clinical-stage inhibitors and degrader",
      "\u226530% tumor volume reductions in a patient-derived xenograft (PDX) model of lung cancer",
      "\u226530% tumor volume reductions in pancreatic and colorectal CDX models"
    ],
    "safety": [
      "pharmacokinetics (PK)",
      "preliminary antitumor activity",
      "safety",
      "tolerability"
    ],
    "evidence": [
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 48
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 49
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 52
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 53
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 54
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 55
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 56
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 57
      },
      {
        "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
        "slide": 58
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "ARV-766",
    "targets": [
      "AR L702H",
      "H875Y",
      "T878X"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "CSPC",
      "castrate-sensitive prostate cancer",
      "mCRPC",
      "metastatic castrate-resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1/2",
      "Phase 2",
      "Phase 3",
      "interim Phase 2"
    ],
    "claims": [
      "3 of 3 patients with co-occurring AR T878/H875/L702H mutations achieved PSA50",
      "42% of patients with AR LBD mutations achieved PSA50",
      "RECIST partial responses observed",
      "addresses an unmet need for durable and tolerable treatments",
      "good tolerability profile",
      "low rates of discontinuation or dose reduction",
      "majority of TRAEs are Grade 1 or 2",
      "no Grade \u22654 TRAEs",
      "precision medicine opportunity",
      "promising efficacy signals",
      "promising efficacy signals in heavily pretreated patients",
      "promising efficacy signals in late-line mCRPC",
      "well-tolerated"
    ],
    "safety": [
      "low rates of discontinuation or dose reduction",
      "majority of TRAEs are Grade 1 or 2",
      "no Grade \u22654 TRAEs",
      "well tolerated to date"
    ],
    "evidence": [
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 1
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 3
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 4
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 5
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 7
      },
      {
        "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
        "slide": 9
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "BCL6",
    "targets": [
      "BCL6"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      ">95% degradation of BCL6 in vivo"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
        "slide": 18
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "Tg25081",
    "targets": [
      "tau"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [
      "tauopathy"
    ],
    "clinical_phases": [],
    "claims": [
      "Dose-Dependently Reduce tau in the Brain of Tauopathy Mice Following Parenteral Administration"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 20
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "PROTAC 1",
    "targets": [
      "p38\u03b1"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "NAPDC 2020-Arvinas-Berlin.pdf",
        "slide": 30
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "AVR-471",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "14 patients were ongoing at the time of data cutoff, including 2 who have been on treatment for >18 months",
      "3 patients had confirmed PRs",
      "40% clinical benefit rate (CBR) in 47 evaluable patients"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "arvinas",
    "program_name": "LRRK2 PROTAC",
    "targets": [
      "LRRK2"
    ],
    "modalities": [
      "PROTAC"
    ],
    "e3_ligases": [],
    "indications": [
      "PSP",
      "Parkinson\u2019s disease",
      "neurodegeneration",
      "tauopathy"
    ],
    "therapeutic_areas": [
      "neurology"
    ],
    "clinical_phases": [],
    "claims": [
      "LRRK2 PROTAC degraders induce reduction of pathologic tau",
      "Reduction of pathologic (AT8) Tau induced by LRRK2 PROTAC",
      "enhances lysosome-based degradation",
      "induces enhanced lysosomal clearance"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 8
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 9
      },
      {
        "document": "Stifel_Neuro_2-14-2024final.pdf",
        "slide": 10
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "NX-5948-203",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "CLL",
      "SLL"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2"
    ],
    "claims": [
      "ORR per iwCLL as assessed by IRC"
    ],
    "safety": [
      "Safety follow-up",
      "Safety run-in"
    ],
    "evidence": [
      {
        "document": "JPM 2026 Investor Presentation FINAL.pdf",
        "slide": 20
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "Bexobrutideg (NX-5948)",
    "targets": [
      "Bruton\u2019s Tyrosine Kinase (BTK)",
      "Bruton\u2019s tyrosine kinase (BTK)"
    ],
    "modalities": [
      "Degrader",
      "degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL)",
      "Waldenstr\u00f6m Macroglobulinemia",
      "relapsed/refractory chronic lymphocytic leukemia (CLL)"
    ],
    "therapeutic_areas": [
      "B Cell Lymphomas",
      "Chronic Lymphocytic Leukemia"
    ],
    "clinical_phases": [
      "Phase 1a/b"
    ],
    "claims": [
      "Demonstrates Rapid and Durable Clinical Responses",
      "High Clinical Activity",
      "Shows High Clinical Activity and Tolerable Safety",
      "Tolerable Safety",
      "demonstrates rapid and durable clinical responses"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 12
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 14
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 29
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "NX-5948",
    "targets": [
      "Bruton\u2019s Tyrosine Kinase (BTK)"
    ],
    "modalities": [
      "degrader"
    ],
    "e3_ligases": [],
    "indications": [
      "CLL",
      "Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL)",
      "Waldenstr\u00f6m Macroglobulinemia"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Ph1a/b",
      "Phase 1a/b"
    ],
    "claims": [
      "Demonstrates Rapid and Durable Clinical Responses",
      "Shows High Clinical Activity and Tolerable Safety"
    ],
    "safety": [],
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 13
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 28
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "NX-5948-301",
    "targets": [],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "CLL",
      "SLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 16
      },
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 17
      }
    ]
  },
  {
    "company": "nurix",
    "program_name": "bexobrutideg (NX-5948)",
    "targets": [
      "BTK"
    ],
    "modalities": [],
    "e3_ligases": [],
    "indications": [
      "SLL",
      "relapsed/refractory CLL"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "CR rate of 4.3%",
      "Median DOR of 20.1 months",
      "Median PFS of 22.1 months",
      "ORR of 83%",
      "higher ORR and superior PFS at the 600 mg dose",
      "well tolerated in a heavily pretreated population"
    ],
    "safety": [
      "tolerable safety profile consistent with prior disclosures"
    ],
    "evidence": [
      {
        "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
        "slide": 27
      }
    ]
  }
]